{"text": "One possible interpretation of the lack of synergy between the two medications is that NRT and varenicline achieve their effects via similar target mechanisms , which overlap to a large or even full extent .", "label": "", "metadata": {}, "score": "35.909836"}
{"text": "Varenicline consistently outperformed buproprion , but unlike the placebo comparisons did not reach statistical significance because of small sample size .In the QuitRx program , scientists investigated the effects of medication alone , abstinence alone and the combination of the two on each of these measures , specifically evaluating symptoms of depression , negative affect -- a person 's mood- and other symptoms of nicotine withdrawal including craving .", "label": "", "metadata": {}, "score": "37.182404"}
{"text": "Varenicline consistently outperformed buproprion , but unlike the placebo comparisons did not reach statistical significance because of small sample size .In the QuitRx program , scientists investigated the effects of medication alone , abstinence alone and the combination of the two on each of these measures , specifically evaluating symptoms of depression , negative affect - a person 's mood- and other symptoms of nicotine withdrawal including craving .", "label": "", "metadata": {}, "score": "37.239113"}
{"text": "The sample size was sufficient to detect small differences in withdrawal ratings and craving and also a clinically meaningful difference in short - term abstinence rates .", "label": "", "metadata": {}, "score": "37.69249"}
{"text": "Ratings of withdrawal symptoms were aggregated to give a composite withdrawal score .One week after the TQD , 35 and 25 participants achieved CO -validated abstinence in the varenicline and placebo groups , respectively .", "label": "", "metadata": {}, "score": "39.330242"}
{"text": "Number of adverse events among participants receiving 2 mg varenicline compared to placebo in the first 3 weeks of pretreatment .[ Time Frame : First 3 weeks of pretreatment ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "41.55928"}
{"text": "The participants were randomized into one of three groups ; varenicline , bupropion or placebo .QuitRx participants were assessed throughout the 12-week medication portion of the program , and also three and six months after quitting .", "label": "", "metadata": {}, "score": "41.99906"}
{"text": "The participants were randomized into one of three groups ; varenicline , bupropion or placebo .QuitRx participants were assessed throughout the 12-week medication portion of the program , and also three and six months after quitting .", "label": "", "metadata": {}, "score": "41.99906"}
{"text": "For example , in our trial , despite evidence of high nicotine dependence in the study population , the success rates in both groups - even in the placebo group - were high .", "label": "", "metadata": {}, "score": "42.407177"}
{"text": "They also reported significantly lower cravings than did those who received the placebo , corresponding to the changes in the brain activity shown with the fMRI scans .", "label": "", "metadata": {}, "score": "42.977554"}
{"text": "Such an effect seems unlikely though , because it would presumably be mediated by lowering of withdrawal discomfort and craving , and these parameters were not affected .", "label": "", "metadata": {}, "score": "43.535652"}
{"text": "Although varenicline has previously been associated with suicidality and depression , side effects were low in this study and declined over time in the varenicline treatment group .", "label": "", "metadata": {}, "score": "43.73243"}
{"text": "Methods .Design overview .Objectives .A double - blind randomised controlled trial was conducted to determine if combining NRT and varenicline provides better withdrawal and craving relief and higher abstinence rates than varenicline alone .", "label": "", "metadata": {}, "score": "44.359856"}
{"text": "2007 ) .Consistent with these rodent studies , two recent human laboratory and open - label studies have reported that varenicline can reduce alcohol self - administration in heavy - drinking smokers ( Fucito et al .", "label": "", "metadata": {}, "score": "45.14421"}
{"text": "There were few dose reductions and temporary discontinuations ( 8 % in varenicline group v 6 % in placebo group ) or permanent discontinuations ( 9 % v 4 % ) because of adverse events ( table 2 ) .", "label": "", "metadata": {}, "score": "45.276524"}
{"text": "In terms of observable effects on smokers , the two medications appear alike although varenicline has antagonist as well as agonist effects .They both seem to achieve their effect on abstinence by alleviating the discomfort of nicotine withdrawal [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "46.191612"}
{"text": "There also remains a possibility of type II error , i.e. that there is a difference but the trial did not detect it .Adding nicotine patches to varenicline did not increase the incidence of nausea or of any other adverse events .", "label": "", "metadata": {}, "score": "46.378887"}
{"text": "Varenicline tartrate and placebo group numbers vary because of missing data .Effects of varenicline preloading on urges to smoke and enjoyment of cigarette .Error bars represent 95 % confidence intervals .", "label": "", "metadata": {}, "score": "46.415688"}
{"text": "\" The authors cautioned that their study only examined the acute effect of a single dose of varenicline , rather than the sustained exposure experienced with regular use of the drug .", "label": "", "metadata": {}, "score": "46.873306"}
{"text": "The therapeutic effects of varenicline when administered as per current labeling rely primarily on the first mechanism ( ie , alleviation of withdrawal discomfort once smokers stop smoking ) .", "label": "", "metadata": {}, "score": "46.934006"}
{"text": "Although some 30 % of participants receiving varenicline reported nausea during the prequit period , equal numbers dropped out in the active and control groups , indicating that varenicline preloading did not generate any excess treatment discontinuation .", "label": "", "metadata": {}, "score": "47.438244"}
{"text": "Varenicline carries a black box warning for suicidal ideation and suicidal behavior and has also been reported to exacerbate depression , hostility , and aggression ( Moore et al .", "label": "", "metadata": {}, "score": "47.862278"}
{"text": "Also , the participants of this trial were all physically and psychologically healthy .Conclusions .Varenicline seems to be effective for smokeless tobacco cessation and has an acceptable safety and tolerability profile .", "label": "", "metadata": {}, "score": "48.16981"}
{"text": "2009 ) .These studies also suggest that varenicline is safe in humans who are using alcohol , an important factor in the development of new pharmacotherapies for individuals with alcohol abuse and/or dependence .", "label": "", "metadata": {}, "score": "48.186115"}
{"text": "The most common adverse event in the varenicline group was nausea , which is consistent with the trials of varenicline for smoking cessation .25 There were few dose reductions or temporary or permanent discontinuations from study drugs , suggesting acceptable tolerability .", "label": "", "metadata": {}, "score": "48.31273"}
{"text": "Which works best ?Neither of these studies looked at which medication worked best at reducing cravings and reward .Rather , they only looked at how each compared with a placebo treatment .", "label": "", "metadata": {}, "score": "48.354454"}
{"text": "1997 ) and is detectable in hair samples for many months ( Appenzeller et al .2007 ) .Here , we assessed the effects of varenicline on both alcohol and cigarette consumption and alcohol craving using electronic diaries , ETG testing , and a battery of behavioral questionnaires .", "label": "", "metadata": {}, "score": "48.560574"}
{"text": "Previous studies , however , have used the same advertisement recruitment method for trials of varenicline for smoking cessation but found lower response rates with placebo .", "label": "", "metadata": {}, "score": "48.628643"}
{"text": "The occurrence of nausea was unrelated to cotinine or CO reduction , to subjective reactions to cigarettes and urges to smoke , to postquit withdrawal discomfort , or to treatment outcome at any time point .", "label": "", "metadata": {}, "score": "48.637024"}
{"text": "Researchers also found that use of varenicline activated an area of the brain that evaluates the rewards associated with the smoking stimulus , helping to blunt the brain 's response to the smoking cues , thus aiding the smoker in determining appropriate actions .", "label": "", "metadata": {}, "score": "48.76684"}
{"text": "Safety and tolerability .Concerning neuropsychiatric adverse events , only sleep disorder ( 10 % v 7 % ) , abnormal dreams ( 8 % v 1 % ) , and insomnia ( 6 % v 3 % ) were higher with varenicline than with placebo ( table 2 ) .", "label": "", "metadata": {}, "score": "49.09856"}
{"text": "Adding nicotine patches to varenicline had no beneficial or detrimental effect on urges to smoke , withdrawal discomfort , abstinence rates , or adverse effects profile .", "label": "", "metadata": {}, "score": "49.19044"}
{"text": "\" It is evident from the findings that varenicline is hitting many more affective targets , in comparison to bupropion or placebo , and there is a distinct benefit of these effects on cessation even among those who do not fully abstain , \" said Cinciripini .", "label": "", "metadata": {}, "score": "49.26216"}
{"text": "\" It is evident from the findings that varenicline is hitting many more affective targets , in comparison to bupropion or placebo , and there is a distinct benefit of these effects on cessation even among those who do not fully abstain , \" said Cinciripini .", "label": "", "metadata": {}, "score": "49.26216"}
{"text": "Another putative mechanism concerns the timing of the treatment regimen of the two medications .Varenicline is used for 1 - 2 weeks prior to quitting , concurrently with smoking .", "label": "", "metadata": {}, "score": "49.345837"}
{"text": "During the prequit period , varenicline and placebo tablets were identically packaged , and the participants in both study arms used the same number of tablets per day .", "label": "", "metadata": {}, "score": "49.64386"}
{"text": "Psychopharmacology ( Berl ) 2008;197 ( 3 ) 371- 377 PubMed Link to Article .Perkins KAMercincavage MFonte CALerman C Varenicline 's effects on acute smoking behavior and reward and their association with subsequent abstinence .", "label": "", "metadata": {}, "score": "49.725975"}
{"text": "The primary outcome concerned urges to smoke .To allow for participant attrition , the study aimed to randomize 100 participants .Varenicline vs placebo differences were assessed using analysis of variance for continuous variables and \u03c7 2 test for categorical variables .", "label": "", "metadata": {}, "score": "49.826836"}
{"text": "The smokers were randomly assigned to a three - week regimen with either varenicline or a placebo .Before and after treatment , each smoker had fMRIs during rest as well as while watching smoking - cue videos .", "label": "", "metadata": {}, "score": "49.83708"}
{"text": "In both study arms , the usual initial dosage of 0.5 mg / d for 3 days was replaced with 1 mg / d .Hence , both study arms used 1 mg of varenicline tartrate per day for their first week of varenicline use ( study week 1 for the varenicline arm and study week 4 for the placebo arm ) and 2 mg / d from the second week onward .", "label": "", "metadata": {}, "score": "50.11917"}
{"text": "By increasing the negative effects of alcohol , varenicline might be most effective in people who are unable to stop consuming alcohol after only one drink , Childs said .", "label": "", "metadata": {}, "score": "50.268593"}
{"text": "Study investigators contacted the IVRS to obtain participants ' identification numbers and double blinded randomised allocations .The dose of varenicline was titrated up during the first week ( 0.5 mg once daily for three days , then 0.5 mg twice daily for four days ) , followed by 1 mg twice daily through week 12 .", "label": "", "metadata": {}, "score": "50.5485"}
{"text": "To assess how this drug influences brain activity , researchers enrolled 30 smokers who were randomly assigned to eight weeks of treatment with either bupropion or a placebo .", "label": "", "metadata": {}, "score": "50.741875"}
{"text": "We performed post hoc analyses for continuous abstinence rates and seven day point rates of abstinence because at baseline more participants in the varenicline group had previously attempted to quit smokeless tobacco than those in the placebo group ( 42 % v 35 % , respectively ) .", "label": "", "metadata": {}, "score": "50.76283"}
{"text": "Varenicline non - responders .Patients who have a weak reaction to varenicline during an extended pre - quit period have been shown to have low success rates [ 5 ] .", "label": "", "metadata": {}, "score": "50.770485"}
{"text": "The sample size of this study was not designed to detect an effect of varenicline preloading at 3 months ' follow - up .Therefore , our striking finding needs to be addressed with caution .", "label": "", "metadata": {}, "score": "51.002388"}
{"text": "Behav Pharmacol 6:359 - 365 PubMed .Moore TJ , Glenmullen J , Furberg CD ( 2010 ) Thoughts and acts of aggression / violence toward others reported in association with varenicline .", "label": "", "metadata": {}, "score": "51.028473"}
{"text": "There was one serious adverse event in the placebo arm ( musculoskeletal injury ) that was unrelated to the study medication .Table 4 shows other adverse events reported by more than 5 % of participants .", "label": "", "metadata": {}, "score": "51.264774"}
{"text": "However , the study provides reassurance that the combination of NRT and varenicline is safe and well tolerated .The present trial was designed to compare varenicline alone with a combination of varenicline and nicotine patch in effects on urges to smoke , and abstinence for up to four weeks .", "label": "", "metadata": {}, "score": "51.301308"}
{"text": "Demographic characteristics of participants at baseline according to allocation to varenicline or placebo for help in cessation of use of smokeless tobacco products .Efficacy .", "label": "", "metadata": {}, "score": "51.317482"}
{"text": "The authors were un - blinded only after the data analysis was completed .Trial medications .Varenicline .Commercial supplies were used as per standard labelling ( 0.5 mg / d for the first 3 days , 1 mg / d on days 4 - 7 , followed by 2 mg / d for the rest of the 12-weeks course ) .", "label": "", "metadata": {}, "score": "51.66585"}
{"text": "Varenicline is more effective than placebo in smokeless tobacco users and has an acceptable safety profile .Participants treated with varenicline were significantly more likely to be abstinent at the end of six months .", "label": "", "metadata": {}, "score": "51.74205"}
{"text": "Importantly , varenicline , a partial agonist at \u03b14\u03b22 nAChRs , reduces both nicotine reward and ethanol seeking and consumption in rodent models ( Chatterjee et al .", "label": "", "metadata": {}, "score": "51.902435"}
{"text": "In an open - label pilot study evaluating combination therapy with varenicline and bupropion SR , the combination was well tolerated with smoking abstinence rates exceeding those observed in prior trials with either drug as monotherapy .", "label": "", "metadata": {}, "score": "52.180992"}
{"text": "This however , was due to a higher depression rating in the nicotine patch arm at TQD ( 1.21 vs 1.43 in the placebo patch and nicotine patch arm , respectively ) , i.e. prior to the initiation of the patch treatment .", "label": "", "metadata": {}, "score": "52.33805"}
{"text": "Conclusion Varenicline can help people to give up smokeless tobacco and has an acceptable safety profile .The response rate in the placebo group in this study was high , suggesting a population less resistant to treatment than smokers .", "label": "", "metadata": {}, "score": "52.546375"}
{"text": "\" This is especially intriguing given the post - marketing data with varenicline that suggests that it may worsen depressive symptoms , \" said Cinciripini .", "label": "", "metadata": {}, "score": "52.73264"}
{"text": "\" This is especially intriguing given the post - marketing data with varenicline that suggests that it may worsen depressive symptoms , \" said Cinciripini .", "label": "", "metadata": {}, "score": "52.73264"}
{"text": "Varenicline , a medication recently approved by the FDA , results in smoking cessation rates as high as 50 % , significantly better than bupropion or placebo .", "label": "", "metadata": {}, "score": "52.740997"}
{"text": "Eight participants did not provide data ( 6 in placebo and 2 in nicotine patch arm ) , among the rest only one participant was not using patches and all were using varenicline .", "label": "", "metadata": {}, "score": "53.031723"}
{"text": "Subjects had 24-h phone access to the study nurse practitioner .Varenicline effects on smoking and alcohol consumption .Study design .This was an outpatient , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "53.164745"}
{"text": "Last , we attempted to determine whether any effects of varenicline preloading plateau within 4 weeks of exposure .In a double - blind randomized design , participants were randomly allocated to receive varenicline for 4 weeks before the TQD or to receive placebo for 3 weeks before the TQD , followed by varenicline for 1 week before the TQD .", "label": "", "metadata": {}, "score": "53.237022"}
{"text": "16 - 20 The finding that the first uptitration week of varenicline use had limited influence , and that such effects needed time to emerge , is of clinical relevance .", "label": "", "metadata": {}, "score": "53.248512"}
{"text": "Findings also indicate that when compared with bupropion , only varenicline reduced the psychological reward , or pleasure derived from smoking , when measured among those who initially lapsed , while trying to retain abstinence during the program .", "label": "", "metadata": {}, "score": "53.34922"}
{"text": "Findings also indicate that when compared with bupropion , only varenicline reduced the psychological reward , or pleasure derived from smoking , when measured among those who initially lapsed , while trying to retain abstinence during the program .", "label": "", "metadata": {}, "score": "53.34922"}
{"text": "After it was approved , several patients treated with varenicline also reported reductions in their drinking , so investigators began to assess if this was an actual effect and how it might be produced .", "label": "", "metadata": {}, "score": "53.372314"}
{"text": "Obach RS , Reed - Hagen AE , Krueger SS , et al .Metabolism and disposition of varenicline , a selective alpha4beta2 acetylcholine receptor partial agonist , in vivo and in vitro .", "label": "", "metadata": {}, "score": "53.374363"}
{"text": "Obach RS , Reed - Hagen AE , Krueger SS , et al .Metabolism and disposition of varenicline , a selective alpha4beta2 acetylcholine receptor partial agonist , in vivo and in vitro .", "label": "", "metadata": {}, "score": "53.374363"}
{"text": "By blocking such receptors , varenicline may be limiting any potentially beneficial effects of NRT as well .E.g. nicotine patches normally alleviate weight gain in continuous abstainers [ 23 ] but they had no such effect here .", "label": "", "metadata": {}, "score": "53.495697"}
{"text": "Error bars represent 95 % confidence intervals .Varenicline tartrate and placebo group numbers vary because of missing data .To further explore the effect of varenicline use on smoking behavior , we subdivided participants according to whether they reduced their cotinine concentrations by more than 50 % ( \" reducers \" ) .", "label": "", "metadata": {}, "score": "53.54265"}
{"text": "In our trial , the smaller differential treatment effect compared with smoking cessation trials could be because of the high placebo response rate , which could suggest lower dependence on nicotine , despite the observed high nicotine dependence as measured by the modified Fagerstr\u00f6m test and salivary cotinine concentrations .", "label": "", "metadata": {}, "score": "53.713234"}
{"text": "In fact , it is a chronic disease that impacts and changes our brain chemistry and function in very specific ways .These studies help explain how medications such as Zyban / Wellbutrin ( bupropion ) and Chantix \u00ae ( varenicline ) help reduce a person 's craving for tobacco and the psychological reward associated with smoking ; they also demonstrate how images of smoking can prompt that craving .", "label": "", "metadata": {}, "score": "53.745808"}
{"text": "While these compounds are effective , they frequently cause unpleasant side effects , compliance is generally low , and relapse following treatment is common ( Bouza et al .", "label": "", "metadata": {}, "score": "53.750835"}
{"text": "Safety and tolerability were also evaluated .Results 431 participants ( 213 varenicline ; 218 placebo ) were randomised and received at least one dose of study drug .", "label": "", "metadata": {}, "score": "53.936626"}
{"text": "Although a previous study suggested that varenicline side effects are not exacerbated in cocaine users ( Poling et al .2010 ) , our results suggest that care should be taken when administering varenicline to alcohol abusers who are concurrently using psychostimulants .", "label": "", "metadata": {}, "score": "54.026527"}
{"text": "MEMS cap data indicated that subjects opened their medication bottles at least once per day an average of 6.2 days / week .There was no significant difference in the number of bottle openings between placebo and varenicline subjects .", "label": "", "metadata": {}, "score": "54.65096"}
{"text": "It was intended as the first \" proof - of - principle \" investigation of the key questions regarding varenicline preloading ; hence , it was not powered for long - term follow - up and did not provide data on abstinence rates beyond 3 months .", "label": "", "metadata": {}, "score": "54.875496"}
{"text": "It alleviates withdrawal discomfort and urges to smoke after smokers stop smoking .3 This effect is ascribed to the action of varenicline on dopaminergic pathways .", "label": "", "metadata": {}, "score": "55.169044"}
{"text": "The present trial was designed to test whether varenicline preloading for 4 weeks reduces urges to smoke and facilitates smoking cessation compared with using the drug for just 1 week before the TQD as per current labeling .", "label": "", "metadata": {}, "score": "55.199127"}
{"text": "We used logistic regression models to analyse the four week and long term continuous abstinence rates with additional terms for baseline salivary cotinine concentration or baseline modified Fagerstr\u00f6m test score and their interaction with treatment .", "label": "", "metadata": {}, "score": "55.258232"}
{"text": "One week after the TQD , 33 ( placebo patch ) and 40 ( nicotine patch ) participants who were abstinent at that time - point provided MPSS ratings .", "label": "", "metadata": {}, "score": "55.258728"}
{"text": "Gonzales D , Rennard SI , Nides M , et al .Varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs sustained - release bupropion and placebo for smoking cessation .", "label": "", "metadata": {}, "score": "55.38273"}
{"text": "Gonzales D , Rennard SI , Nides M , et al .Varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs sustained - release bupropion and placebo for smoking cessation .", "label": "", "metadata": {}, "score": "55.38273"}
{"text": "Such hypotheses have not been experimentally evaluated so far .One observational study from an in - patient smoking cessation facility found no differences in outcome between a cohort of patients receiving various combinations of NRT products plus varenicline and a cohort receiving various combinations of NRT products alone or with bupropion [ 4 ] .", "label": "", "metadata": {}, "score": "55.533634"}
{"text": "Gonzales D , Rennard SI , Nides M , Oncken C , Azoulay S , Billing CB , et al .Varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs sustained - release bupropion and placebo for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "55.632378"}
{"text": "The typical dose schedule for varenicline involves a 1 week pretreatment phase prior to quitting smoking ( Gonzales et al . , 2006 ; Jorenby et al . , 2006 ; Nides et al . , 2006 ) .", "label": "", "metadata": {}, "score": "55.690376"}
{"text": "Please refer to The JAMA Network 's Privacy Policy for additional information .Hajek P , McRobbie HJ , Myers KE , Stapleton J , Dhanji A. Use of Varenicline for 4 Weeks Before Quitting Smoking : Decrease in Ad Lib Smoking and Increase in Smoking Cessation Rates .", "label": "", "metadata": {}, "score": "55.861"}
{"text": "13 Varenicline could be expected to help users quit smokeless tobacco because of its mechanism of action .It can stimulate the release of sufficient dopamine to reduce craving and withdrawal while simultaneously acting as a partial antagonist , thereby blocking the binding of nicotine to the receptors - and consequently the reinforcing effects of nicotine intake 14 -and reducing the likelihood of a full relapse .", "label": "", "metadata": {}, "score": "56.10154"}
{"text": "( from ' no urges ( 1 ) ' to ' extremely strong ( 6 ) ' ) .The two items are aggregated to give a composite craving score .", "label": "", "metadata": {}, "score": "56.126812"}
{"text": "The occurrence of nausea was unrelated to other effects of the drug and seems to be mediated by mechanisms other than those responsible for the influence of the drug on smoking .", "label": "", "metadata": {}, "score": "56.27364"}
{"text": "Compares the number of participants who reported an adverse event in the extended varenicline pretreatment versus short - term varenicline pretreatment conditions during the 3-week placebo controlled pretreatment phase .", "label": "", "metadata": {}, "score": "56.289185"}
{"text": "Furthermore , it is consistent with animal studies indicating that alcohol and nicotine act through a common reward pathway that involves the NAChR ( Bito - Onon et al .", "label": "", "metadata": {}, "score": "56.311172"}
{"text": "There is a widespread interest in combining NRT and varenicline in the hope of improving treatment outcomes .The results of this study suggest that such practice may not be productive or economical , although further trials would be useful to exclude the possibility of type II error .", "label": "", "metadata": {}, "score": "56.423023"}
{"text": "Jorenby DE , Hays JT , Rigotti NA , Azoulay S , Watsky EJ , Williams KE , et al .Efficacy of varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs placebo or sustained - release bupropion for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "56.43171"}
{"text": "Those effects upon the subjective response to alcohol could reduce drinking in people prone to bingeing and other forms of abuse .\" We found that varenicline increased the unpleasant effects of alcohol and decreased drug liking , \" said Emma Childs , PhD , research associate at the University of Chicago Medicine and first author of the study published in Alcoholism : Clinical and Experimental Research . \"", "label": "", "metadata": {}, "score": "56.460728"}
{"text": "After an alcoholic drink , self - reported dysphoria was increased while alcohol effects on subconscious eye movements ( a measure of the drugs ' objective effects ) were reduced .", "label": "", "metadata": {}, "score": "56.556656"}
{"text": "PubMed View Article .Hajek P , McRobbie HJ , Myers KE , Stapleton J , Dhanji AR : Use of varenicline for 4 weeks before quitting smoking : decrease in ad lib smoking and increase in smoking cessation rates .", "label": "", "metadata": {}, "score": "56.68"}
{"text": "The latter effect has been demonstrated for both varenicline [ 5 - 9 ] and NRT [ 10 , 11 ] , although the evidence for the NRT effect seems weak [ 11 ] .", "label": "", "metadata": {}, "score": "56.72187"}
{"text": "The trial results have a practical implication .Finding a positive effect would indicate that a large - scale study with a long - term follow - up is warranted , but it would not provide a definitive proof of efficacy .", "label": "", "metadata": {}, "score": "57.00753"}
{"text": "Outcomes were biochemically confirmed .Conclusions and Relevance Among cigarette smokers , combined use of varenicline and bupropion , compared with varenicline alone , increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks .", "label": "", "metadata": {}, "score": "57.152157"}
{"text": "In people using smokeless tobacco products , varenicline resulted in significantly higher rates of continuous abstinence in the last four weeks of treatment and after a further 14 weeks ' follow - up after treatment .", "label": "", "metadata": {}, "score": "57.15548"}
{"text": "McKee SA , Harrison EL , O'Malley SS , Krishnan - Sarin S , Shi J , Tetrault JM , Picciotto MR , Petrakis IL , Estevez N , Balchunas E ( 2009 ) Varenicline reduces alcohol self - administration in heavy - drinking smokers .", "label": "", "metadata": {}, "score": "57.331978"}
{"text": "J Subst Abuse 7:245 - 252 PubMed CrossRef .Whitworth AB , Fischer F , Lesch OM , Nimmerrichter A , Oberbauer H , Platz T , Potgieter A , Walter H , Fleischhacker WW ( 1996 ) Comparison of acamprosate and placebo in long - term treatment of alcohol dependence .", "label": "", "metadata": {}, "score": "57.470837"}
{"text": "Our findings also suggest that varenicline use may have a role in harm reduction .Although various harm reduction approaches remain controversial , there is increasing acceptance among health professionals and government bodies that for some \" hard - core \" smokers , harm reduction is an option that merits serious consideration .", "label": "", "metadata": {}, "score": "57.540012"}
{"text": "In the placebo group , there were only 5 reducers , and their abstinence rates did not differ from those of the others in their group .", "label": "", "metadata": {}, "score": "57.552746"}
{"text": "Varenicline potentiates alcohol - induced negative subjective responses and offsets impaired eye movements .Alcoholism : Clinical and Experimental Research , 2012 .University of Chicago Medical Center .", "label": "", "metadata": {}, "score": "57.592964"}
{"text": "Exploration of combination therapy with existing drugs may provide the best opportunity to advance treatment in the absence of any new pharmacotherapies for tobacco dependence .", "label": "", "metadata": {}, "score": "57.652473"}
{"text": "\" We 're told that the vast majority of real - world varenicline users use it without any formal counseling or support .If true , why design yet another varenicline trial that fails to reveal varenicline 's worth as a stand alone quitting aid ?", "label": "", "metadata": {}, "score": "57.713326"}
{"text": "Despite these constraints , the study findings are novel and potentially important .The results concerning the effect of varenicline preloading on ad lib smoking are clear and robust .", "label": "", "metadata": {}, "score": "57.768852"}
{"text": "To test this hypothesis , we evaluated separately the effect of nicotine patches on participants who did not reduce their CO reading by 50 % or more during their pre - TQD varenicline dosing .", "label": "", "metadata": {}, "score": "57.79876"}
{"text": "The lack of reduction in smoke intake may provide guidance for dosage increase , assuming that for nonreacting patients , a dosage increase would generate the desirable effects .", "label": "", "metadata": {}, "score": "57.852795"}
{"text": "56- 63 PubMed Link to Article .Gonzales DRennard SINides M et al .Varenicline Phase 3 Study Group , Varenicline , an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist , vs sustained - release bupropion and placebo for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "57.976562"}
{"text": "56- 63 PubMed Link to Article .Gonzales DRennard SINides M et al .Varenicline Phase 3 Study Group , Varenicline , an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist , vs sustained - release bupropion and placebo for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "57.976562"}
{"text": "If more subjects had actually quit smoking , it might have been interesting to compare drinking between quitters and nonquitters .In the absence of this comparison , it is not possible to determine how much of the effect of varenicline on drinking was secondary to its effect on smoking .", "label": "", "metadata": {}, "score": "58.19091"}
{"text": "Our primary objective was to examine the efficacy of varenicline 1 mg twice daily compared with placebo for cessation of smokeless tobacco after 12 weeks of treatment .", "label": "", "metadata": {}, "score": "58.297943"}
{"text": "1995 ) .Furthermore , animal studies indicate that neuronal nicotinic acetylcholine receptors ( nAChRs ) , also contribute to the rewarding effects of alcohol ( Bito - Onon et al .", "label": "", "metadata": {}, "score": "58.30862"}
{"text": "In previous smoking cessation studies with varenicline and bupropion SR , no significant increases in anxiety were observed with either varenicline or bupropion SR compared with placebo .", "label": "", "metadata": {}, "score": "58.445602"}
{"text": "If this were the case , treatment efficacy could be improved by switching smokers who show no reaction to varenicline during the pre - quit period over to NRT .", "label": "", "metadata": {}, "score": "58.474655"}
{"text": "An important unanswered question concerns the optimal varenicline preloading period .The effects of varenicline use on smoke intake in the intervention group seemed to slow down between weeks 3 and 4 compared with weeks 1 and 3 , but they did not plateau .", "label": "", "metadata": {}, "score": "58.601685"}
{"text": "Jorenby DE , Hays JT , Rigotti NA , et al .Efficacy of varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs placebo or sustained - release bupropion for smoking cessation .", "label": "", "metadata": {}, "score": "58.665913"}
{"text": "Jorenby DE , Hays JT , Rigotti NA , et al .Efficacy of varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , vs placebo or sustained - release bupropion for smoking cessation .", "label": "", "metadata": {}, "score": "58.665913"}
{"text": "Varenicline , taken orally , was administered in an open - label fashion and dispensed in blister packs .Participants started with a recommended oral dosage of 0.5 mg once daily for 3 days , titrated to 0.5 mg twice daily for days 4 to 7 , and then to the maintenance dose of 1 mg twice daily ( total , 2 mg / d ) for 11 weeks .", "label": "", "metadata": {}, "score": "58.967297"}
{"text": "All subjects that experienced an AE in the varenicline group were also positive for psychostimulants at their last study visit .ECG data obtained at baseline and week 12 did not indicate any effect of drug treatment on cardiovascular function .", "label": "", "metadata": {}, "score": "59.176872"}
{"text": "Since there is a high comorbidity between nicotine and alcohol dependence , a single medication that could decrease the use of both substances would be ideal . \" Funding for the research was provided by the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism .", "label": "", "metadata": {}, "score": "59.190483"}
{"text": "Fig 2 Continuous abstinence rates with varenicline versus placebo achieved at end of treatment .Continuous abstinence rates analysed with logistic regression models with terms for study centre and treatment group .", "label": "", "metadata": {}, "score": "59.29771"}
{"text": "Jorenby DEHays JTRigotti NA et al .Varenicline Phase 3 Study Group , Efficacy of varenicline , an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist , vs placebo or sustained - release bupropion for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "59.36592"}
{"text": "Additionally , our cotinine results suggest that , although subjects were smoking significantly less at the end of the 12 weeks of varenicline treatment , they were , by and large , still smoking .", "label": "", "metadata": {}, "score": "59.38421"}
{"text": "1996 ; Wright and Moore 1990 ) , indicating a need for more effective therapeutic approaches .Heavy alcohol and nicotine use commonly occur in the same individual ( Toneatto et al .", "label": "", "metadata": {}, "score": "59.40677"}
{"text": "4 , 5 Opportunities exist for additive or synergistic therapeutic effects from combination therapy with these 2 medications .Combination pharmacotherapy for treating tobacco dependence may increase smoking abstinence compared with monotherapy .", "label": "", "metadata": {}, "score": "59.48037"}
{"text": "Bouza C , Angeles M , Magro A , Mu\u00f1oz A , Amate J ( 2004 )Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence : a systematic review .", "label": "", "metadata": {}, "score": "59.625645"}
{"text": "This latter participant was a man aged 56 with a two year history of hypertension who was also taking candesartan and amlodipine .He took varenicline for 56 days , and he had stopped using smokeless tobacco .", "label": "", "metadata": {}, "score": "59.779873"}
{"text": "Bupropion SR ( sustained - release ) and varenicline are nonnicotine pharmacotherapies indicated for tobacco - dependence treatment .Bupropion SR may mediate effects through noradrenergic and dopaminergic systems 2 with a competitive inhibitory effect on nicotinic acetylcholine receptors .", "label": "", "metadata": {}, "score": "59.78962"}
{"text": "Participants with missing smoking status information were adjudicated as smoking .Sample size was based on reported smoking abstinence rates in previous trials of varenicline 16 , 17 and a minimum detectible odds ratio ( OR ) of 1.7 for the comparison of varenicline and bupropion SR vs varenicline and placebo .", "label": "", "metadata": {}, "score": "59.86827"}
{"text": "Perkins KAMercincavage MFonte CALerman C Varenicline 's effects on acute smoking behavior and reward and their association with subsequent abstinence .Psychopharmacology ( Berl ) 2010;210 ( 1 ) 45- 51 PubMed Link to Article .", "label": "", "metadata": {}, "score": "60.055866"}
{"text": "This is possible , but any gains in potentially higher efficacy of short - acting NRT products are usually undermined by the fact that oral NRT products and nicotine nasal spray have more side effects and are less user - friendly then patches and generate lower adherence .", "label": "", "metadata": {}, "score": "60.233326"}
{"text": "The safety and efficacy of varenicline in cocaine using smokers maintained on methadone : a pilot study .Am J Addict 19:401 - 408 PubMed CrossRef .", "label": "", "metadata": {}, "score": "60.3153"}
{"text": "Participants were randomly assigned to receive varenicline + bupropion SR ( combination therapy ) ; or varenicline + matching bupropion SR placebo ( varenicline monotherapy ) .", "label": "", "metadata": {}, "score": "60.38945"}
{"text": "Changes in withdrawal symptom ratings from the TQD to 24 hours and 1 week were compared using repeated - measures analysis of variance .Differences were to be adjusted for all baseline characteristics related to outcome that differed between the 2 groups .", "label": "", "metadata": {}, "score": "60.487602"}
{"text": "Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post - TQD .Medication use and smoking status were established at 1 , 4 and 12 weeks .", "label": "", "metadata": {}, "score": "60.699814"}
{"text": "TQD indicates target quit date .A total of 63 participants ( 34 receiving varenicline and 29 receiving placebo ) reported abstinence at 24 hours after their TQD and provided data on urges to smoke .", "label": "", "metadata": {}, "score": "60.791462"}
{"text": "Medication may help .There are very few studies that compare treatments to each other to see which work best , but both Chantix and Zyban / Wellbutrin appear to be effective in helping to reduce nicotine cravings .", "label": "", "metadata": {}, "score": "60.79592"}
{"text": "This suggests that patients with varenicline preloading who stopped smoking on the TQD were less likely to relapse than those with placebo preloading .Early quitters normally form the bulk of longer - term abstainers , with patients who start hesitantly or experience lapses tending to return to smoking .", "label": "", "metadata": {}, "score": "60.805893"}
{"text": "That 's what researchers found in two recent studies reported in the Archives of General Psychiatry .Both studies were done at the Center for the Study of Addictions at the University of Pennsylvania .", "label": "", "metadata": {}, "score": "60.845913"}
{"text": "Combination therapy was associated with significantly higher prolonged smoking abstinence rates at 12 and 26 weeks compared with varenicline monotherapy ( Table 2 ) .No significant differences were observed in prolonged smoking abstinence rates between the 2 groups at 52 weeks .", "label": "", "metadata": {}, "score": "60.86918"}
{"text": "Please refer to The JAMA Network 's Privacy Policy for additional information .Ebbert JO , Hatsukami DK , Croghan IT , et al .Combination Varenicline and Bupropion SR for Tobacco - Dependence Treatment in Cigarette Smokers : A Randomized Trial .", "label": "", "metadata": {}, "score": "60.880615"}
{"text": "Varenicline use was accompanied by standard weekly support sessions as provided by the National Health Service Stop - Smoking Service in the United Kingdom .9 The study was authorized by the United Kingdom Medicines and Healthcare Products Regulatory Agency .", "label": "", "metadata": {}, "score": "60.94285"}
{"text": "Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice .Addiction 1995;90 ( 1 ) 31- 42 PubMed Link to Article .", "label": "", "metadata": {}, "score": "61.003857"}
{"text": "Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice .Addiction 1995;90 ( 1 ) 31- 42 PubMed Link to Article .", "label": "", "metadata": {}, "score": "61.003857"}
{"text": "These adverse events were coded using the Medical Dictionary for Regulatory Activities ( MedDRA ) .Adverse events were recorded from the time of the first dose of study treatment up to 28 days after the last dose was taken .", "label": "", "metadata": {}, "score": "61.093018"}
{"text": "The occurrence of nausea may limit this option somewhat , but individualized dosaging may be possible and useful .Smoking cessation interventions typically target the aftermath of smoking cessation .", "label": "", "metadata": {}, "score": "61.207573"}
{"text": "In the placebo group , one participant developed colon cancer , one ruptured an Achilles tendon , and one experienced cardiac failure .None of these was thought to be related to treatment .", "label": "", "metadata": {}, "score": "61.259323"}
{"text": "Prior to the smoking quit date , subjects will be randomized to receive either extended pretreatment with varenicline ( titration up to 1 mg ) for 4 weeks or short - term varenicline pretreatment ( 3 weeks placebo followed by 1 week of varenicline ) .", "label": "", "metadata": {}, "score": "61.37315"}
{"text": "If a significant interaction effect was detected , supplemental analyses were performed to compare treatment outcomes within subgroups defined by the characteristic .The MNWS - R was completed daily .", "label": "", "metadata": {}, "score": "61.418243"}
{"text": "Discussion .We find that varenicline attenuates alcohol consumption in smokers .Varenicline also reduces reported cumulative consumption of alcohol and ongoing consumption , as measured using the objective marker ETG .", "label": "", "metadata": {}, "score": "61.47103"}
{"text": "Conclusions .The efficacy of varenicline was not enhanced by the addition of nicotine patches , although further trials would be useful to exclude the possibility of type II error .", "label": "", "metadata": {}, "score": "61.476986"}
{"text": "One participant in the placebo arm lost 5.5 kg .Removing this outlier made the difference non - significant .There were no differences or trends emerging for any other single withdrawal symptom at any time - point .", "label": "", "metadata": {}, "score": "61.618576"}
{"text": "The provision of double placebo to smokers seeking treatment also poses ethical issues .Finding varenicline plus patches more effective than varenicline plus placebo on the other hand would imply beneficial effects of the combination .", "label": "", "metadata": {}, "score": "61.626152"}
{"text": "2011 ; Hendrickson et al .2010 ; Steensland et al .2007 ) .Although our data indicate that the varenicline - induced reduction of alcohol consumption is independent of the effects of varenicline on smoking , additional studies must be conducted in nonsmoking drinkers to definitively determine whether varenicline would be effective in individuals who do not smoke .", "label": "", "metadata": {}, "score": "61.678017"}
{"text": "We know from a study reported recently in Biological Psychiatry that people differ in their reaction to smoking - related cues as measured by fMRIs .", "label": "", "metadata": {}, "score": "61.691486"}
{"text": "For this study , reported abstinence rates and treatment comparisons need to be interpreted with the knowledge that 38 % of participants did not complete the study .", "label": "", "metadata": {}, "score": "61.94583"}
{"text": "The same 3 variables plus older age predicted continuous abstinence at 12 weeks .Using varenicline for 4 weeks before the TQD , as opposed to starting 1 week before the TQD , reduced smoke intake , urges to smoke , and enjoyment of cigarettes during the prequit period .", "label": "", "metadata": {}, "score": "62.06066"}
{"text": "Methods .117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch ( 15 mg/16 hour ) .", "label": "", "metadata": {}, "score": "62.06962"}
{"text": "J Clin Psychiatry 59(Suppl 20):22 - 33 , quiz 34 - 57 PubMed .Steensland P , Simms JA , Holgate J , Richards JK , Bartlett SE ( 2007 ) Varenicline , an alpha4beta2 nicotinic acetylcholine receptor partial agonist , selectively decreases ethanol consumption and seeking .", "label": "", "metadata": {}, "score": "62.08805"}
{"text": "Researchers monitored the effects of the drink on cardiovascular and eye movement measures , and subjects filled out questionnaires to report the subjective effects of the drink .", "label": "", "metadata": {}, "score": "62.13241"}
{"text": "Study medication was labeled and dispensed according to participant identification , ensuring that treatment assignment remained concealed from the participant , investigators , and all study personnel having participant contact .", "label": "", "metadata": {}, "score": "62.172028"}
{"text": "In a Cochrane meta - analysis of 12 studies from 2007 , behavioural interventions were found to be effective . 10 In contrast , pharmacological treatments have not proved effective . 10 A more recent randomised placebo controlled trial showed a non - significant trend towards efficacy with a 4 mg nicotine lozenge ( 1.5 , 0.7 to 2.1 ) .", "label": "", "metadata": {}, "score": "62.236393"}
{"text": "Volunteers were included if they were 18 years or older , had no contraindication for varenicline use , had not used varenicline in the past 6 months , and had no current psychiatric or other serious illness .", "label": "", "metadata": {}, "score": "62.308395"}
{"text": "During each 45-second video , participants were told to either allow their cravings or to resist cravings ; they then voted on the strength of those cravings .", "label": "", "metadata": {}, "score": "62.361412"}
{"text": "Suppressing other withdrawal symptoms .Smokers are also subject to other withdrawal symptoms when they try to quit including loss of concentration and craving for tobacco .", "label": "", "metadata": {}, "score": "62.420334"}
{"text": "Suppressing other withdrawal symptoms .Smokers are also subject to other withdrawal symptoms when they try to quit including loss of concentration and craving for tobacco .", "label": "", "metadata": {}, "score": "62.420334"}
{"text": "Our use of nontreatment - seeking drinkers also allowed us to isolate the effects of drug treatment without influence from other psychosocial strategies , such as Alcoholics Anonymous , group therapy , family support , etc . that treatment seekers may simultaneously pursue in an effort to decrease their intake .", "label": "", "metadata": {}, "score": "62.518433"}
{"text": "( 5 ) 912- 923 PubMed Link to Article .Hajek PMcRobbie HGillison F Dependence potential of nicotine replacement treatments : effects of product type , patient characteristics , and cost to user .", "label": "", "metadata": {}, "score": "62.69758"}
{"text": "( 5 ) 912- 923 PubMed Link to Article .Hajek PMcRobbie HGillison F Dependence potential of nicotine replacement treatments : effects of product type , patient characteristics , and cost to user .", "label": "", "metadata": {}, "score": "62.69758"}
{"text": "Tonstad S , Davies S , Flammer M , Russ C , Hughes J. Psychiatric adverse events in randomized , double - blind , placebo - controlled clinical trials of varenicline : a pooled analysis .", "label": "", "metadata": {}, "score": "62.711872"}
{"text": "Nicotine from NRT acts on nAChRs in a similar manner to nicotine from tobacco smoke , but delivery from NRT is much slower .It is not clear if the central effects of the two medications are sufficiently different to allow synergy , but if they do differ , their combination could have several beneficial effects .", "label": "", "metadata": {}, "score": "62.768826"}
{"text": "Trials with longer follow - up periods are needed to corroborate these findings .Figures in this Article .The \u03b14\u03b22 nicotinic receptor partial agonist varenicline tartrate is an effective smoking cessation medication .", "label": "", "metadata": {}, "score": "62.839996"}
{"text": "Eligible participants were randomised to one of two parallel treatment arms in a 1:1 ratio ( varenicline : placebo ) by using a telephone interactive voice response system ( IVRS ) .", "label": "", "metadata": {}, "score": "63.204636"}
{"text": "Prochaska JJ , Hilton JF : Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation : systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "63.21375"}
{"text": "The primary outcome measures were calculated as both alcoholic drinks per week and cigarettes per week , as well as alcohol craving per week ( OCDS ) .", "label": "", "metadata": {}, "score": "63.223053"}
{"text": "2002 ; Toneatto et al .1992 ) , the use of objective markers of alcohol consumption provides important confirmatory data in studies of treatment efficacy .", "label": "", "metadata": {}, "score": "63.328545"}
{"text": "2011 ) .Though anecdotal , it is of interest that all four of the AEs that occurred in subjects on active study drug were associated with concurrent psychostimulant use .", "label": "", "metadata": {}, "score": "63.428017"}
{"text": "Experimental : Short - term Varenicline Pretreatment .Report exceeding maximum weekly drinking limits every week in the past 4 weeks and exceeding maximum daily drinking limits on at least 1 occasion in the past 4 weeks .", "label": "", "metadata": {}, "score": "63.489197"}
{"text": "Varenicline can produce a sustained decrease in alcohol consumption in individuals who also smoke .Further studies are warranted to assess varenicline efficacy in treatment - seeking alcohol abusers who do not smoke and to ascertain the relationship between varenicline effects on smoking and drinking .", "label": "", "metadata": {}, "score": "63.572166"}
{"text": "Neither outcome was significant at 52 weeks .Our observed rates of prolonged smoking abstinence with varenicline monotherapy were consistent with those of previous varenicline studies at all time points .", "label": "", "metadata": {}, "score": "63.600563"}
{"text": "22 Our results suggest that varenicline use may be a viable and possibly more effective alternative .Of course , it is possible that after an extended period of use , the benefit of varenicline therapy may weaken or disappear .", "label": "", "metadata": {}, "score": "63.60455"}
{"text": "Analyses were conducted using SAS statistical software ( version 9.3 , SAS Institute Inc ) .Overall study completion rates were 62 % ( 315 participants ) , 63 % ( 158 participants ) in the varenicline and bupropion SR group ( combination therapy ) and 61 % ( 157 participants ) in the varenicline and placebo group ( varenicline monotherapy ) .", "label": "", "metadata": {}, "score": "63.71794"}
{"text": "Varenicline Phase 3 Study Group , Efficacy of varenicline , an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist , vs placebo or sustained - release bupropion for smoking cessation : a randomized controlled trial .", "label": "", "metadata": {}, "score": "63.721558"}
{"text": "West RBaker CLCappelleri JCBushmakin AG Effect of varenicline and bupropion SR on craving , nicotine withdrawal symptoms , and rewarding effects of smoking during a quit attempt .", "label": "", "metadata": {}, "score": "63.725555"}
{"text": "In varenicline monotherapy , the 3 events included food poisoning , diverticulitis , and breast cancer .No events were adjudicated to be related to study medication .", "label": "", "metadata": {}, "score": "63.833527"}
{"text": "Results .92 % of participants used both medications during the first week after the TQD .The combination treatment generated no increase in nausea or other adverse effects .", "label": "", "metadata": {}, "score": "63.85839"}
{"text": "Fourteen participants ( 7 receiving varenicline and 7 receiving placebo ) dropped out before attempting to stop smoking .They are included in the results as nonabstainers .", "label": "", "metadata": {}, "score": "63.945568"}
{"text": "Pharmacological profile of the \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline , an effective smoking cessation aid .Neuropharmacology 2007 ; 52 : 985 -94 .", "label": "", "metadata": {}, "score": "63.957024"}
{"text": "Rationale .Emerging evidence suggests that the \u03b14\u03b22 form of the nicotinic acetylcholine receptor ( nAChR ) modulates the rewarding effects of alcohol .Objectives .", "label": "", "metadata": {}, "score": "64.01414"}
{"text": "4 The second effect consists of a reduction in the enjoyment of smoking and in smoke intake .This is presumed to be caused by the drug 's blocking of the receptors that would otherwise facilitate the \" reward \" experienced when smoking .", "label": "", "metadata": {}, "score": "64.20327"}
{"text": "Objective To determine efficacy and safety of varenicline and bupropion sustained - release ( SR ; combination therapy ) compared with varenicline ( monotherapy ) in cigarette smokers .", "label": "", "metadata": {}, "score": "64.45616"}
{"text": "On the TQD they were randomised to either a nicotine or placebo patch .Demographic details , smoking history , and the Fagerstrom Test for Nicotine Dependence ( FTND ) [ 16 ] , were collected at baseline .", "label": "", "metadata": {}, "score": "64.61139"}
{"text": "Tsai ST , Cho HJ , Cheng HS , Kim CH , Hsueh KC , Billing CB Jr , et al .A randomized , placebo - controlled trial of varenicline , a selective \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist , as a new therapy for smoking cessation in Asian smokers .", "label": "", "metadata": {}, "score": "64.7053"}
{"text": "Adherance to medications .Table 2 shows adherence to medication use at different time points .There was no difference between the two study arms at any time point .", "label": "", "metadata": {}, "score": "64.706116"}
{"text": "MHRA : .UK Medicines and healthcare products regulatory agency .Declarations .Acknowledgements .The study was supported by an investigator - initiated grant from Pfizer , who also supplied varenicline .", "label": "", "metadata": {}, "score": "64.85611"}
{"text": "It had a marginal effect on early quit rates but had a significant effect on promoting abstinence at 12 weeks .The effect was particularly strong among participants who in response to varenicline use substantially reduced their smoke intake during the ad lib smoking preloading period .", "label": "", "metadata": {}, "score": "64.961105"}
{"text": "Alcohol - dependent subjects were excluded .During the screening visit , subjects were asked if they were currently or had ever been treatment - seeking for alcohol abuse or dependence , and those that reported in the affirmative were excluded from the study .", "label": "", "metadata": {}, "score": "65.212296"}
{"text": "When measuring the effects of abstinence alone on emotional functioning , the study found that regardless of which medication the smoker received , people who were able to abstain from smoking had lower scores for overall negative affect , anxiety and sadness but also showed higher positive affect .", "label": "", "metadata": {}, "score": "65.21501"}
{"text": "When measuring the effects of abstinence alone on emotional functioning , the study found that regardless of which medication the smoker received , people who were able to abstain from smoking had lower scores for overall negative affect , anxiety and sadness but also showed higher positive affect .", "label": "", "metadata": {}, "score": "65.21501"}
{"text": "The first study looked at bupropion .Originally developed as an antidepressant and marketed as Wellbutrin , bupropion is now also prescribed as the stop - smoking aid Zyban .", "label": "", "metadata": {}, "score": "65.29413"}
{"text": "Coe JW , Brooks PR , Vetelino MG , et al .Varenicline : an \u03b14\u03b22 nicotinic receptor partial agonist for smoking cessation .J Med Chem .", "label": "", "metadata": {}, "score": "65.33498"}
{"text": "Coe JW , Brooks PR , Vetelino MG , et al .Varenicline : an \u03b14\u03b22 nicotinic receptor partial agonist for smoking cessation .J Med Chem .", "label": "", "metadata": {}, "score": "65.33498"}
{"text": "Bito - Onon JJ , Simms JA , Chatterjee S , Holgate J , Bartlett SE ( 2011 )Varenicline , a partial agonist at neuronal nicotinic acetylcholine receptors , reduces nicotine - induced increases in 20 % ethanol operant self - administration in Sprague - Dawley rats .", "label": "", "metadata": {}, "score": "65.35687"}
{"text": "No events were adjudicated to be related to study medication .Preplanned exploratory analyses were performed to assess potential moderators of the effect of treatment on abstinence .", "label": "", "metadata": {}, "score": "65.43853"}
{"text": "Thorax 2008 , 63 : 717 - 724 .PubMed View Article .West R , Baker CL , Cappelleri JC , Bushmakin AG : Effect of varenicline and bupropion SR on craving , nicotine withdrawal symptoms , and rewarding effects of smoking during a quit attempt .", "label": "", "metadata": {}, "score": "65.589294"}
{"text": "As with all studies , there were some potential limitations with this trial .Varenicline is currently not licensed for smokeless tobacco cessation , and more studies with longer follow - up might be needed to evaluate longer term efficacy .", "label": "", "metadata": {}, "score": "65.60248"}
{"text": "A controlled trial of sustained - release bupropion , a nicotine patch , or both for smoking cessation .N Engl J Med .Ebbert JO , Croghan IT , Sood A , et al .", "label": "", "metadata": {}, "score": "65.67712"}
{"text": "A controlled trial of sustained - release bupropion , a nicotine patch , or both for smoking cessation .N Engl J Med .Ebbert JO , Croghan IT , Sood A , et al .", "label": "", "metadata": {}, "score": "65.67712"}
{"text": "The use of oral smokeless tobacco is prevalent in some areas .Current cessation options have focused on brief behavioural interventions .Varenicline has known efficacy among smokers trying to quit .", "label": "", "metadata": {}, "score": "65.68947"}
{"text": "Nicotine ( 15 mg/16 hours ) and placebo patches were identically packaged .Participants received a box containing a four - week supply ( 28 patches ) on their TQD .", "label": "", "metadata": {}, "score": "65.80138"}
{"text": "We did not include study arms using placebo varenicline .Varenicline is superior to nicotine patches across the time period of our study [ 8 , 13 , 14 ] .", "label": "", "metadata": {}, "score": "65.84207"}
{"text": "Schmitt G , Droenner P , Skopp G , Aderjan R ( 1997 ) Ethyl glucuronide concentration in serum of human volunteers , teetotalers , and suspected drinking drivers .", "label": "", "metadata": {}, "score": "65.88858"}
{"text": "Damaj MI , Carroll FI , Eaton JB , et al .Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors .", "label": "", "metadata": {}, "score": "65.94531"}
{"text": "Damaj MI , Carroll FI , Eaton JB , et al .Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors .", "label": "", "metadata": {}, "score": "65.94531"}
{"text": "During treatment , subjects were required to report daily alcohol and cigarette use online via online diaries on a secure study server .Subjects had until midnight to record the previous day 's substance use .", "label": "", "metadata": {}, "score": "66.14941"}
{"text": "In routine use , the majority of smokers receiving intensive support and either of these two medications are likely to fail in their attempt to quit [ 3 ] .", "label": "", "metadata": {}, "score": "66.34996"}
{"text": "Therefore , it is possible that extended pretreatment with varenicline may also yield better cessation outcomes than the standard 1 week lead in period .This may be particularly true if pretreatment also reduces alcohol consumption prior to the quit attempt .", "label": "", "metadata": {}, "score": "66.46692"}
{"text": "Where the expectation is that the product will be used only occasionally , as a supplement to another treatment , the adherence is likely to be low .", "label": "", "metadata": {}, "score": "66.48122"}
{"text": "PubMed View Article .McRobbie H , Hajek P : Effects of rapid smoking on post - cessation urges to smoke .Addiction 2007 , 102 : 483 - 489 .", "label": "", "metadata": {}, "score": "66.50641"}
{"text": "Whenever possible , every effort was made to document participants ' outcomes such as abstinence , reasons for withdrawal , and safety status .If a participant withdrew from the trial and also withdrew consent for disclosure of future information , no further evaluations were performed , and no additional data were collected .", "label": "", "metadata": {}, "score": "66.55692"}
{"text": "Analytical methods were chosen and reviewed in consultation with the UCSF Biostatistical Core .Results .Demographics and retention .Drug cycle populations were demographically well - matched for variables including gender , education , ethnicity , and age ( Table 1 ) .", "label": "", "metadata": {}, "score": "66.59417"}
{"text": "A possible analogy might be exposure to appealing and unappealing food .The level of hunger pangs may be the same , but it is easier to resist a food that has become less tempting .", "label": "", "metadata": {}, "score": "66.62845"}
{"text": "On the rating scale , 1 represents much more enjoyable ; 2 , same as before ; and 3 , much less enjoyable .Incidence of nausea among participants at each time point during the first 4 weeks of the study .", "label": "", "metadata": {}, "score": "66.6646"}
{"text": "Significance tests for the treatment comparison ( varenicline v placebo ) were performed at the two sided 0.05 level , and the 95 % confidence intervals were two sided .", "label": "", "metadata": {}, "score": "66.69164"}
{"text": "Outcome measures included number of alcoholic drinks per week , cigarettes per week , amount of alcohol craving per week , cumulative cigarettes and alcoholic drinks consumed during the treatment period , number of abstinent days , and weekly percentage of positive ethyl glucuronide and cotinine screens .", "label": "", "metadata": {}, "score": "66.81271"}
{"text": "The study had only a short - term follow - up .This however , would limit the generalisability of the results primarily if the results were positive .", "label": "", "metadata": {}, "score": "66.92522"}
{"text": "Conclusions Although several issues remain to be clarified , varenicline preloading can generate a substantial reduction in ad lib smoking and enhance 12-week quit rates .", "label": "", "metadata": {}, "score": "66.95608"}
{"text": "However , drop - out rate was comparable between the 2 groups and comparable with previous trials using varenicline for smoking cessation .16 , 17 Additional analyses using multiple imputation to accommodate missing data were performed .", "label": "", "metadata": {}, "score": "66.97411"}
{"text": "In subsequent analyses , we used salivary cotinine concentration as the principal marker for smoke intake change because cotinine concentrations are not influenced by smoking shortly before visits and are the most accurate objective indicator of overall smoke intake .", "label": "", "metadata": {}, "score": "67.11231"}
{"text": "Error bars represent 95 % confidence intervals .Varenicline tartrate and placebo group numbers vary because of missing data .On the rating scale , 1 represents much more enjoyable ; 2 , same as before ; and 3 , much less enjoyable .", "label": "", "metadata": {}, "score": "67.16184"}
{"text": "Schuurmans MMDiacon AHvan Biljon XBolliger CT Effect of pre - treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch : a randomized controlled trial .", "label": "", "metadata": {}, "score": "67.24831"}
{"text": "Schuurmans MMDiacon AHvan Biljon XBolliger CT Effect of pre - treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch : a randomized controlled trial .", "label": "", "metadata": {}, "score": "67.24831"}
{"text": "Bupropion SR was titrated 1 tablet ( 150 mg ) by mouth once per day for days 1 to 3 , then 1 tablet by mouth twice per day ( total of 300 mg / d ) for a total of 12 weeks .", "label": "", "metadata": {}, "score": "67.33147"}
{"text": "Subjects ' own reasons for leaving the study were rarely related to concerns about the efficacy , or lack thereof , of the study drug .", "label": "", "metadata": {}, "score": "67.3379"}
{"text": "Shiffman S , Ferguson SG : The effect of a nicotine patch on cigarette craving over the course of the day : results from two randomized clinical trials .", "label": "", "metadata": {}, "score": "67.499146"}
{"text": "Figure 3 shows that the 2 groups started to diverge during the initial uptitration week and converged again when the control group switched to varenicline 1 week before the TQD .", "label": "", "metadata": {}, "score": "67.60924"}
{"text": "Study drug .Study drug was provided by Pfizer pharmaceuticals and was reconstituted ( to add riboflavin and to match placebo in appearance ) and blinded by Abbotts Compounding Pharmacy in Berkeley , CA , USA .", "label": "", "metadata": {}, "score": "67.75154"}
{"text": "Nicotine dependence .Metabolic measures of consumption .Relationship between smoking and drinking .Abstinence .Varenicline did not affect the number of days completers reported being abstinent from alcohol , suggesting that , during varenicline treatment , subjects maintained their pattern of initiating alcohol consumption , but drank less once drinking was initiated .", "label": "", "metadata": {}, "score": "67.88122"}
{"text": "This finding is more tentative than the main result because there was a trend in favour of nicotine patches and the study was not powered for sub sample analyses .", "label": "", "metadata": {}, "score": "67.89093"}
{"text": "Background .Nicotine replacement therapy ( NRT ) and varenicline are both effective in helping smokers quit .There is growing interest in combining the two treatments to improve treatment outcomes , but no experimental data exist on whether this is efficacious .", "label": "", "metadata": {}, "score": "67.894485"}
{"text": "Participants completed tobacco craving and nicotine withdrawal assessments using a daily diary containing the Minnesota Nicotine Withdrawal Scale , Revised ( MNWS - R ) .", "label": "", "metadata": {}, "score": "68.00275"}
{"text": "Standard drinks and alcohol content were calculated from the information provided .Subjects also used their electronic diaries to report medication use , to report any nonstudy - related illness , to keep notes on side effects , and to report anything else they felt might be of interest to the experimenters .", "label": "", "metadata": {}, "score": "68.06573"}
{"text": "Differences in urges to smoke at 24 hours and one week were compared using one way ANOVA .Changes in withdrawal symptom ratings from TQD to 24 h and one week were assessed using repeated measures ANOVA .", "label": "", "metadata": {}, "score": "68.318924"}
{"text": "Alcohol consumption .Since cumulative drinking also diverged for varenicline and placebo treatment groups at week 3 ( Fig .1b ) , chi square analysis was conducted on drinking data from weeks 3 to 11 ( when taper down was initiated ) . 1d ) .", "label": "", "metadata": {}, "score": "68.37467"}
{"text": "Measures included smoking satisfaction and smoke intake before quitting , urges to smoke and withdrawal discomfort after quitting , and sustained abstinence from the TQD to 3 months .", "label": "", "metadata": {}, "score": "68.413216"}
{"text": "Addiction 2009;104 ( 9 )1597- 1602 PubMed Link to Article .2008 PHS Guideline Update Panel , Liaisons , and Staff , Treating tobacco use and dependence : 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary .", "label": "", "metadata": {}, "score": "68.46694"}
{"text": "Addiction 2009;104 ( 9 )1597- 1602 PubMed Link to Article .2008 PHS Guideline Update Panel , Liaisons , and Staff , Treating tobacco use and dependence : 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary .", "label": "", "metadata": {}, "score": "68.46694"}
{"text": "The Mood and Physical Symptoms Scale ( MPSS ) , 11 which assesses tobacco withdrawal symptoms and urges to smoke , was completed at all contacts up to week 8 .", "label": "", "metadata": {}, "score": "68.473"}
{"text": "The participants were weighed at baseline and 4 weeks after TQD .On arrival at the TQD session , participants were sequentially allocated to the study medication by the study staff , using a list that was computer generated by the study statistician ( M.S. ) .", "label": "", "metadata": {}, "score": "68.49663"}
{"text": "Among cigarette smokers , combined use of varenicline and bupropion , compared with varenicline alone , resulted in an increase in prolonged abstinence but not 7-day point - prevalence at 12 and 26 weeks ; neither outcome was significantly different at 52 weeks .", "label": "", "metadata": {}, "score": "68.499146"}
{"text": "Adverse events were collected at each contact .Any reports of sickness , nausea , or vomiting were recorded as \" nausea present .\" On arrival to the first study session , participants were sequentially allocated to study medication using a list that was computer generated by the study statistician ( J.S. ) .", "label": "", "metadata": {}, "score": "68.58928"}
{"text": "The primary efficacy end point was the continuous abstinence rate over the last four weeks of study treatment ( weeks 9 - 12 ) , defined as proportion of participants who reported abstaining from smokeless tobacco during the indicated period confirmed by cotinine measurements during clinic visits .", "label": "", "metadata": {}, "score": "68.65638"}
{"text": "A baseline score was calculated using MNWS - R data completed prior to starting medication .Scores obtained for the first 16 days after the target quit date were analyzed as change from baseline .", "label": "", "metadata": {}, "score": "68.72308"}
{"text": "In addition , the participants in this trial might have been less resistant to cessation than corresponding populations of smokers , who have long been under pressure to quit .", "label": "", "metadata": {}, "score": "68.80873"}
{"text": "Data for primary outcome measures were analyzed in two separate ways : ( 1 ) using all subjects randomized to treatment and ( 2 ) using subjects that completed all 12 weeks of study drug .", "label": "", "metadata": {}, "score": "68.8226"}
{"text": "Subjects were instructed to take their medication twice daily .Riboflavin ( 25 mg ) , which causes urine samples to fluoresce under ultraviolet ( UV ) light , was added to both drug and placebo capsules to monitor drug compliance .", "label": "", "metadata": {}, "score": "68.82811"}
{"text": "Interventions Twelve weeks of varenicline and bupropion SR or varenicline and placebo .Main Outcomes and Measures Primary outcome was abstinence rates at week 12 , defined as prolonged ( no smoking from 2 weeks after the target quit date ) abstinence and 7-day point - prevalence ( no smoking past 7 days ) abstinence .", "label": "", "metadata": {}, "score": "68.88086"}
{"text": "Participants were instructed to take tablets orally with water .Compliance with treatment was documented at all study visits and at the end of treatment visit during week 12 .", "label": "", "metadata": {}, "score": "68.959946"}
{"text": "Nicotine Tob Res .Croghan IT , Trautman JA , Winhusen T , et al .Tobacco dependence counseling in a randomized multisite clinical trial .", "label": "", "metadata": {}, "score": "69.09344"}
{"text": "Nicotine Tob Res .Croghan IT , Trautman JA , Winhusen T , et al .Tobacco dependence counseling in a randomized multisite clinical trial .", "label": "", "metadata": {}, "score": "69.09344"}
{"text": "Diabetes mellitus requiring insulin or oral hypoglycemic medications .Baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg .", "label": "", "metadata": {}, "score": "69.10065"}
{"text": "\" It also suggests that those who were able to abstain from smoking will ultimately feel better than those who continue to smoke .\"The study also found that compared to the non - abstainers , abstainers using either bupropion or varenicline experienced lower levels of sadness , but in terms of overall depressive symptoms the varenicline group fared much better .", "label": "", "metadata": {}, "score": "69.104645"}
{"text": "\" It also suggests that those who were able to abstain from smoking will ultimately feel better than those who continue to smoke .\"The study also found that compared to the non - abstainers , abstainers using either bupropion or varenicline experienced lower levels of sadness , but in terms of overall depressive symptoms the varenicline group fared much better .", "label": "", "metadata": {}, "score": "69.104645"}
{"text": "17 ] , which assesses tobacco withdrawal symptoms and urges to smoke was completed at all contacts .The items are analysed separately and also aggregated to give a composite MPSS score .", "label": "", "metadata": {}, "score": "69.17874"}
{"text": "A considerable proportion of participants in the active group ( 36.7 % ) reduced their smoke intake by more than 50 % , assessed objectively by changes in cotinine concentrations .", "label": "", "metadata": {}, "score": "69.2553"}
{"text": "HOUSTON -- Smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo - unmedicated assisted smoking cessation -according to a study published in the journal JAMA Psychiatry . \"", "label": "", "metadata": {}, "score": "69.574554"}
{"text": "Wright C , Moore R ( 1990 ) Disulfiram treatment of alcoholism .Am J Med 88:647 - 655 PubMed CrossRef .Wurst FM , Kempter C , Seidl S , Alt A ( 1999 ) Ethyl glucuronide - a marker of alcohol consumption and a relapse marker with clinical and forensic implications .", "label": "", "metadata": {}, "score": "69.73571"}
{"text": "Mean Percentage of Heavy Drinking Days Comparing Participants in the Extended Varenicline Pretreatment Versus Short - term Varenicline Pretreatment Conditions [ Time Frame : First 3 weeks ( pretreatment ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.76268"}
{"text": "Clin Ther 2007 ; 29 : 1040 -56 .Rigotti NA , Pipe AL , Benowitz NL , Arteaga C , Garza D , Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease : a randomized trial .", "label": "", "metadata": {}, "score": "69.77284"}
{"text": "The ratings of nausea were not included in the composite MPSS score .A six - point scale is used to rate ' How much of the time have you felt the urge to smoke in the past week ? '", "label": "", "metadata": {}, "score": "69.83235"}
{"text": "He explains the net effect of lower withdrawal and psychological reward improves the overall odds of cessation success , which is consistent with other research .", "label": "", "metadata": {}, "score": "70.00453"}
{"text": "He explains the net effect of lower withdrawal and psychological reward improves the overall odds of cessation success , which is consistent with other research .", "label": "", "metadata": {}, "score": "70.00453"}
{"text": "Adverse events occurring in at least 2 % of one of the study groups are listed in Table 3 .During the medication phase or within 7 days of stopping medication , 4 serious adverse events ( SAEs ) occurred .", "label": "", "metadata": {}, "score": "70.0084"}
{"text": "However , subjects were not excluded from the study if they failed to adhere to the quit date or if they chose not to attend the offered group therapy for smoking cessation , mitigating the pressure to actually quit smoking .", "label": "", "metadata": {}, "score": "70.29213"}
{"text": "Although several issues remain to be clarified , varenicline preloading generates a substantial reduction in ad lib smoking and may have a potential for harm reduction .", "label": "", "metadata": {}, "score": "70.419334"}
{"text": "Varenicline , or Chantix , is different from bupropion because it both reduces the symptoms of nicotine withdrawal and decreases the psychological reinforcement or reward from nicotine use .", "label": "", "metadata": {}, "score": "70.73111"}
{"text": "27 The strong effects of varenicline preloading on precessation variables and the fact that the influence on abstinence was significantly related to reduced smoking during the preloading period suggest that the phenomenon is likely genuine , but further studies are needed to verify this .", "label": "", "metadata": {}, "score": "70.78093"}
{"text": "T\u00f3masson K , Vaglum P ( 1995 )A nationwide representative sample of treatment - seeking alcoholics : a study of psychiatric comorbidity .Acta Psychiatr Scand 92:378 - 385 PubMed CrossRef .", "label": "", "metadata": {}, "score": "70.782745"}
{"text": "Was this varenicline trial blind ?Was this pre - quitting varenicline study blind as claimed ?If one - third of the pre - quitting active group reduced smoking by greater than 50 % prior to quitting day , do the authors suggest that this substantial reduction went unnoticed by participants ?", "label": "", "metadata": {}, "score": "70.859634"}
{"text": "The current treatment schedule , which commences 1 week before quitting , relies primarily on the first mechanism .We set out to determine whether increasing the prequit medication period renders cigarettes less satisfying and facilitates quitting .", "label": "", "metadata": {}, "score": "71.03856"}
{"text": "While such improvements are typical in studies that involve constant monitoring and care of a clinical population , these data may also reflect the rigorous exclusion of subjects with comorbid disorders .", "label": "", "metadata": {}, "score": "71.24927"}
{"text": "Br J Addict 1991;86 ( 9 )1119- 1127 PubMed Link to Article .Cappelleri JCBushmakin AGBaker CLMerikle EOlufade AOGilbert DG Confirmatory factor analyses and reliability of the Modified Cigarette Evaluation Questionnaire .", "label": "", "metadata": {}, "score": "71.273575"}
{"text": "Br J Addict 1991;86 ( 9 )1119- 1127 PubMed Link to Article .Cappelleri JCBushmakin AGBaker CLMerikle EOlufade AOGilbert DG Confirmatory factor analyses and reliability of the Modified Cigarette Evaluation Questionnaire .", "label": "", "metadata": {}, "score": "71.273575"}
{"text": "Number of Participants Reporting Continuous Smoking Abstinence in the Extended Varenicline Pretreatment Versus Short - term Varenicline Pretreatment Conditions .[ Time Frame : Last 4 weeks of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "71.33984"}
{"text": "Frequency of adverse events was compared between groups using the Fisher exact test .In all cases , 2-tailed P values were reported with values less than or equal to .05 considered statistically significant .", "label": "", "metadata": {}, "score": "71.69835"}
{"text": "Your health care provider can explain possible side effects associated with these medications .Nicotine replacement patches , gum and lozenges can be purchased at any drugstore .", "label": "", "metadata": {}, "score": "71.86869"}
{"text": "Demographic details , health status , smoking history , and results of the Fagerstr\u00f6m Test for Nicotine Dependence 10 were collected at baseline .Salivary cotinine samples were collected at baseline , week 3 , and week 4 ( TQD ) .", "label": "", "metadata": {}, "score": "72.099495"}
{"text": "History of clinically significant allergic reactions .Exhibit serious psychiatric illness ( i.e. , schizophrenia , bipolar disorder , severe major depression , panic disorder , borderline personality disorder , organic mood or mental disorders , or substantial suicide or violence risk ) by history or psychological examination ) .", "label": "", "metadata": {}, "score": "72.15968"}
{"text": "Ethyl glucuronide ( ETG ) is a metabolite that is formed when ethanol interacts with glucuronic acid ( Wurst et al .1999 ) and is now commonly used to assay alcohol consumption .", "label": "", "metadata": {}, "score": "72.18338"}
{"text": "Copyright .\u00a9 Hajek et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd.Smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo -- unmedicated assisted smoking cessation -- according to a study published in the journal JAMA Psychiatry . \"", "label": "", "metadata": {}, "score": "72.28102"}
{"text": "Br J Addict 86:1119 - 1127 PubMed CrossRef .Heffernan TM , Moss M , Ling J ( 2002 ) Subjective ratings of prospective memory deficits in chronic heavy alcohol users .", "label": "", "metadata": {}, "score": "72.32348"}
{"text": "A medication commonly used to help people stop smoking may have an unanticipated positive side effect for an entirely different vice : drinking alcohol .A new study by University of Chicago researchers finds that varenicline , sold as Chantix , increases the negative effects of alcohol and therefore could hold promise as a treatment for alcoholism .", "label": "", "metadata": {}, "score": "72.50578"}
{"text": "He recovered the same day and underwent carotid Doppler ultrasonography five days later , with normal results .The investigator judged the event of loss of consciousness as related to study medication and the traffic incident as related to the loss of consciousness .", "label": "", "metadata": {}, "score": "72.62683"}
{"text": "Anton RF , Moak DH , Latham PK ( 1996 )The obsessive compulsive drinking scale : a new method of assessing outcome in alcoholism treatment studies .", "label": "", "metadata": {}, "score": "72.903496"}
{"text": "Condition ICMJE .Nicotine Dependence .Smoking .Heavy Drinking .Intervention ICMJE .Drug : Varenicline .Other Name : chantix .Study Arm ( s ) .", "label": "", "metadata": {}, "score": "73.187225"}
{"text": "View Article .Heatherton TF , Kozlowski LT , Frecker RC , Fagerstrom KO : The Fagerstrom Test for Nicotine Dependence : a revision of the Fagerstrom Tolerance Questionnaire .", "label": "", "metadata": {}, "score": "73.18768"}
{"text": "Analyses included all participants who took at least one dose of study medication .Participants who discontinued the study were classified as still using smokeless tobacco for the remainder of the study .", "label": "", "metadata": {}, "score": "73.23158"}
{"text": "Predictors of alcohol abusers ' inconsistent self - reports of their drinking and life events .Alcohol Clin Exp Res 16:542 - 546 PubMed CrossRef .", "label": "", "metadata": {}, "score": "73.254"}
{"text": "PubMed View Article .Hajek P , West R , Foulds J , Nilsson F , Burrows S , Meadow A : Randomized comparative trial of nicotine polacrilex , a transdermal patch , nasal spray , and an inhaler .", "label": "", "metadata": {}, "score": "73.35372"}
{"text": "If not , why ?Blinding concerns become apparent when contrasting varenciline 's 4-week 2009 - 10 UK NHS Stop Smoking Services quitting rate of 60%3 to both this study 's 4-week placebo rate of 33 % and its extended pre - quitting use rate of 49 % .", "label": "", "metadata": {}, "score": "73.4894"}
{"text": "Five occurred in the combination therapy group and included acute coronary syndrome , deep vein thrombosis complicated by acute coronary syndrome , prostate cancer , a new coronary artery disease diagnosis , and pneumothorax .", "label": "", "metadata": {}, "score": "73.56129"}
{"text": "Rose JE , Brauer LH , Behm FM , Cramblett M , Calkins K , Lawhon D ( 2004 )Psychopharmacological interactions between nicotine and ethanol .", "label": "", "metadata": {}, "score": "73.79994"}
{"text": "Competing interests .PH and HM have received research funding from , and provided consultancy to manufacturers of smoking cessation medications .Authors ' contributions .", "label": "", "metadata": {}, "score": "73.87044"}
{"text": "Serious adverse events could also include any adverse event that the sponsor or investigators considered serious enough to be classified as such .If any adverse events or their sequelae persisted , follow - up was required until resolution or stabilisation occurred at a level acceptable to the investigator and sponsor .", "label": "", "metadata": {}, "score": "73.87158"}
{"text": "West R , Hajek P , Stead L , Stapleton J : Outcome criteria in smoking cessation trials : proposal for a common standard .Addiction 2005 , 100 : 299 - 303 .", "label": "", "metadata": {}, "score": "74.0105"}
{"text": "J Neurosci 30:10169 - 10176 PubMed CrossRef .Howard J ( 1992 ) Subject recruitment and retention issues in longitudinal research involving substance - abusing families : a clinical services context .", "label": "", "metadata": {}, "score": "74.14551"}
{"text": "6 The proactive questioning seems to have led to increased reporting of adverse effects compared with the usual reactive collection of self - reported symptoms .", "label": "", "metadata": {}, "score": "74.470085"}
{"text": "Items were rated on a 5-point scale ranging from 0 ( not present ) to 4 ( severe ) and reported symptoms for the previous day .", "label": "", "metadata": {}, "score": "74.60621"}
{"text": "There is a tendency to \" medicalize \" the treatment of tobacco use by just giving someone a pill and thinking that 's all that we need to do .", "label": "", "metadata": {}, "score": "74.702034"}
{"text": "Aubin HJBobak ABritton JR et al .Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised open - label trial .Thorax 2008;63 ( 8) 717- 724 PubMed Link to Article .", "label": "", "metadata": {}, "score": "75.11673"}
{"text": "Aubin HJBobak ABritton JR et al .Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised open - label trial .Thorax 2008;63 ( 8) 717- 724 PubMed Link to Article .", "label": "", "metadata": {}, "score": "75.11673"}
{"text": "Heavy drinking defined as consuming 4 or more drinks per occasion for women and 5 or more drinks per occasion for men .Drinking in the final week of pretreatment prior to the quit - date is not included because both groups were receiving active varenicline during this period .", "label": "", "metadata": {}, "score": "75.229706"}
{"text": "The two pharmaceutical companies had no involvement in the design and conduct of the study , analysis and interpretation of the data , or preparation of the manuscript .", "label": "", "metadata": {}, "score": "75.269516"}
{"text": "J Public Health ( Oxf ) 2009 , 32 : 71 - 82 .Ebbert JO , Burke MV , Hays JT , Hurt RD : Combination treatment with varenicline and nicotine replacement therapy .", "label": "", "metadata": {}, "score": "75.302124"}
{"text": "When I lead support groups , I talk about just how powerful this addiction is so that family members can be more understanding and supportive of the person trying to quit - that 's very important .", "label": "", "metadata": {}, "score": "75.3788"}
{"text": "Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence .Addict Behav 2003 ; 28 : 1203 -18 .Harris KJ , Okuyemi KS , Catley D , Mayo MS , Ge B , Ahluwalia JS .", "label": "", "metadata": {}, "score": "75.46566"}
{"text": "The scores were chosen to represent a ratio of about 1:1:2 of participants and were tested for simple linear relations to the outcomes .Possible scores on the modified Fagerstr\u00f6m test ranged from 1 to 10 ( observed scores ranged from 3 to 10 ) .", "label": "", "metadata": {}, "score": "75.5193"}
{"text": "Cahill K , Stead LF , Lancaster T : Nicotine receptor partial agonists for smoking cessation .Cochrane Database Syst Rev 2011 ., 2 : CD006103 .", "label": "", "metadata": {}, "score": "75.57655"}
{"text": "Point prevalences of abstinence analysed with logistic regression models with terms for study centre and treatment group .There were no significant differences in treatment effect across centres , although there were 16 study centres and the number of participants in some centres was low .", "label": "", "metadata": {}, "score": "75.931885"}
{"text": "We used 16 h/15 mg patch which has extensive evidence of its efficacy [ 18 ] .The 24 hour patch has been shown to have stronger effects on morning urges to smoke [ 21 ] , but both types of patches have the same effect on smoking cessation outcomes [ 1 ] .", "label": "", "metadata": {}, "score": "75.96689"}
{"text": "15 16 We evaluated the efficacy and safety of varenicline compared with placebo for the cessation of use of smokeless tobacco .Methods .Study design .", "label": "", "metadata": {}, "score": "76.11098"}
{"text": "An AE was defined as either a \" severe \" rating on any of the side effects scale questions or an unanticipated study termination due to side effects .", "label": "", "metadata": {}, "score": "76.18676"}
{"text": "She oversees inpatient and outpatient tobacco treatment and support services .Abstract .Objective To assess the efficacy and safety of varenicline ( a licensed cigarette smoking cessation aid ) in helping users of smokeless tobacco to quit .", "label": "", "metadata": {}, "score": "76.263626"}
{"text": "The potential health risks of smokeless tobacco were discussed only in response to a query from a participant .Assessments .Baseline assessments occurred during the first visit and included assessment of demography , medical history , concomitant use of drugs , physical examination , blood pressure , heart rate , and body weight .", "label": "", "metadata": {}, "score": "76.3049"}
{"text": "24 Tobacco withdrawal has also been associated with both anxiety and depressive symptoms .25 All patients being treated with pharmacotherapy for tobacco dependence should be monitored for changes in anxiety and mood , an approach consistent with standard clinical practice .", "label": "", "metadata": {}, "score": "76.71718"}
{"text": "Meta - analyses have suggested that bupropion SR attenuates postcessation weight gain more than varenicline at the end of treatment .18 In previous trials , mean weight gain with varenicline among smoking - abstinent participants from baseline to 12 weeks was 2.37 kg 16 and 2.89 kg , 17 and 2.12 kg 16 and 1.88 kg 17 for bupropion SR .", "label": "", "metadata": {}, "score": "76.784225"}
{"text": "When we treat diabetes or high cholesterol , we may give a patient medicine , but we also teach them about making positive lifestyle changes and offer support .", "label": "", "metadata": {}, "score": "76.78734"}
{"text": "Hays JT , Ebbert JO .Adverse effects and tolerability of medications for the treatment of tobacco use and dependence .Drugs .Foulds J , Stapleton J , Hayward M , et al .", "label": "", "metadata": {}, "score": "76.80061"}
{"text": "Hays JT , Ebbert JO .Adverse effects and tolerability of medications for the treatment of tobacco use and dependence .Drugs .Foulds J , Stapleton J , Hayward M , et al .", "label": "", "metadata": {}, "score": "76.80061"}
{"text": "Also helpful are nicotine replacement therapies such as nicotine gum , patches and lozenges , especially when used in combination with Zyban / Wellbutrin .You do n't use nicotine replacement products with Chantix because this medication mimics the effects of nicotine on the body , helping thwart the addictive cravings .", "label": "", "metadata": {}, "score": "76.86897"}
{"text": "23 Herein , experience of a marked medication adverse effect had no influence on quit rates or on withdrawal discomfort ratings .Helping the type of smoker who can not quit on his or her own is a tough task , and expectations alone seem to be of little assistance .", "label": "", "metadata": {}, "score": "76.93386"}
{"text": "Are weight concerns predictive of smoking cessation ?J Consult Clin Psychol .Clark MM , Hurt RD , Croghan IT , et al .The prevalence of weight concerns in a smoking abstinence clinical trial .", "label": "", "metadata": {}, "score": "76.95125"}
{"text": "Are weight concerns predictive of smoking cessation ?J Consult Clin Psychol .Clark MM , Hurt RD , Croghan IT , et al .The prevalence of weight concerns in a smoking abstinence clinical trial .", "label": "", "metadata": {}, "score": "76.95125"}
{"text": "View Article .Fiore MC , Smith SS , Jorenby DE , Baker TB : The effectiveness of the nicotine patch for smoking cessation , A meta - analysis .", "label": "", "metadata": {}, "score": "77.09931"}
{"text": "Smoking behavior seems to be driven by positive reinforcement ( ie , by seeking rewards associated with smoking ) and by negative reinforcement ( ie , by avoiding withdrawal discomfort ) .", "label": "", "metadata": {}, "score": "77.2374"}
{"text": "Psychopharmacology ( Berl ) 215:655 - 663 CrossRef .Garza D , Murphy M , Tseng LJ , Riordan HJ , Chatterjee A ( 2011 )", "label": "", "metadata": {}, "score": "77.362976"}
{"text": "Medication was dispensed at baseline and at weeks 3 , 4 , 6 , and 8 .Participants received a single payment of \u00a3 30 , contingent on their attending after week 4 .", "label": "", "metadata": {}, "score": "77.49659"}
{"text": "Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Varenicline for Smoking Cessation in Heavy Drinking Smokers .Official Title ICMJE .", "label": "", "metadata": {}, "score": "77.5372"}
{"text": "Gender .Both .Ages .18 Years to 75 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Stop - smoking medications do reduce cravings , studies show .", "label": "", "metadata": {}, "score": "77.76388"}
{"text": "Some people lose control of their alcohol consumption during a drinking episode , for example they may aim to only have one or two drinks but end up drinking say four or five .", "label": "", "metadata": {}, "score": "77.77188"}
{"text": "NRT : .Nicotine replacement therapy .SD : .Standard deviation .MPSS : .The mood and physical symptoms scale .TQD : .", "label": "", "metadata": {}, "score": "77.785675"}
{"text": "Neither drug helped reduce the physical symptoms associated with withdrawal from tobacco , such as restlessness , insomnia or increased appetite .Audrey Darville , ARNP Tobacco Cessation .", "label": "", "metadata": {}, "score": "77.87717"}
{"text": "Any unexplained elevations in liver enzymes ( i.e. , transaminases , bilirubin ) .Clinically significant cardiovascular disease .Uncontrolled hypertension .Hepatic or renal impairment .", "label": "", "metadata": {}, "score": "78.07475"}
{"text": "Cigarette consumption .Since cumulative smoking diverged for varenicline and placebo treatment groups at week 3 ( Fig .1a ) , chi square analysis was conducted on smoking data from weeks 3 to 11 ( when taper down was initiated ) .", "label": "", "metadata": {}, "score": "78.107666"}
{"text": "The trial took place at the Tobacco Dependence Research Unit , Wolfson Institute of Preventive Medicine , Queen Mary University of London .Outcomes and follow - up .", "label": "", "metadata": {}, "score": "78.11536"}
{"text": "Continuous smoking abstinence rates comparing extended versus short pretreatment of 2 mg varenicline .[ Time Frame : Last 4 weeks of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "78.11626"}
{"text": "Family support and understanding are key , as is talking with your health care provider about which approach is best for you .Quitting is a process , and if you lapse or relapse , that 's just part of the process .", "label": "", "metadata": {}, "score": "78.37378"}
{"text": "Additionally , medication bottles were all equipped with Medication Event Monitoring System caps ( MEMS caps ; AARDEX , Zurich , Switzerland ) , which recorded the time of each cap removal , and subjects were instructed to only open their medication bottles to take their study drug .", "label": "", "metadata": {}, "score": "78.3962"}
{"text": "\" When smokers try to quit , many are likely to experience a range of nicotine withdrawal symptoms , including negative mood , difficulty concentrating , irritability and even depressive symptoms making quitting difficult and increases the chances of relapse . \"", "label": "", "metadata": {}, "score": "78.483444"}
{"text": "\" When smokers try to quit , many are likely to experience a range of nicotine withdrawal symptoms , including negative mood , difficulty concentrating , irritability and even depressive symptoms making quitting difficult and increases the chances of relapse . \"", "label": "", "metadata": {}, "score": "78.483444"}
{"text": "Depressive symptomatology was assessed using the Beck Depression Inventory , second edition .9 The Columbia - Suicide Severity Rating Scale assessed for suicidal ideation or behaviors . 8 Both assessments were completed at baseline and weeks 2 , 4 , 8 , 14 , 26 , and 52 .", "label": "", "metadata": {}, "score": "78.557655"}
{"text": "Biologic samples were collected only at baseline , week 3 , and the TQD .Only participants who provided data at all time points are included .", "label": "", "metadata": {}, "score": "78.633736"}
{"text": "We find that varenicline ( Chantix \u2122 ) is effective at inhibiting not only cigarette smoking , as previously reported , but also inhibits alcohol consumption in a population of heavy drinkers who were not seeking treatment for their drinking .", "label": "", "metadata": {}, "score": "78.80395"}
{"text": "Use of another investigational drug within 30 days .Intention to donate blood or blood products during the treatment phase of the study .Use of tobacco products other than cigarettes or use of marijuana .", "label": "", "metadata": {}, "score": "78.80423"}
{"text": "Models included effects for treatment group , study day , and the treatment \u00d7 study - day interaction .Analyses were performed using all days for each participant and also using only data collected prior to the first reported tobacco use following the target quit date .", "label": "", "metadata": {}, "score": "78.97563"}
{"text": "Saunders JB , Aasland OG , Babor TF , de la Fuente JR , Grant M ( 1993 ) Development of the Alcohol Use Disorders Identification Test ( AUDIT ) : WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption - II .", "label": "", "metadata": {}, "score": "79.02756"}
{"text": "Patton JH , Stanford MS , Barratt ES ( 1995 )Factor structure of the Barratt impulsiveness scale .J Clin Psychol 51:768 - 774 PubMed CrossRef .", "label": "", "metadata": {}, "score": "79.04006"}
{"text": "Acknowledgments .This study was supported in part by AA019429 - 01 and by funds provided by the State of California for medical research on alcohol and substance abuse .", "label": "", "metadata": {}, "score": "79.041115"}
{"text": "Smoking rates are elevated among drinkers compared to non - drinkers ( Marks et al . , 1997 ) .Moreover , there is some evidence that both smokers who drink alcohol are less successful quitting smoking ( Leeman , Huffman , & O'Malley , 2007 ) .", "label": "", "metadata": {}, "score": "79.092285"}
{"text": "Rose JE et al , Effectiveness of Extended - Duration Transdermal Nicotine Therapy : A Randomized Trial ANN INTERN MED ( 2010 ) 152(3 ) : 144 - 151 .", "label": "", "metadata": {}, "score": "79.09512"}
{"text": "Funding / Support : This study was supported by an investigator - initiated grant from Pfizer ( Dr Hajek ) , who also supplied the study medication .", "label": "", "metadata": {}, "score": "79.26523"}
{"text": "Mooney MWhite THatsukami D The blind spot in the nicotine replacement therapy literature : assessment of the double - blind in clinical trials .Addict Behav 2004;29 ( 4 ) 673- 684 PubMed Link to Article .", "label": "", "metadata": {}, "score": "79.39978"}
{"text": "Mooney MWhite THatsukami D The blind spot in the nicotine replacement therapy literature : assessment of the double - blind in clinical trials .Addict Behav 2004;29 ( 4 ) 673- 684 PubMed Link to Article .", "label": "", "metadata": {}, "score": "79.39978"}
{"text": "View Article .Shiffman S , Ferguson SG : Nicotine patch therapy prior to quitting smoking : a meta - analysis .Addiction 2008 , 103 : 557 - 563 .", "label": "", "metadata": {}, "score": "79.48388"}
{"text": "Participants were encouraged to quit smoking 1 week into study drug treatment and were offered weekly group therapy sessions to aid in this endeavor .Three subjects participated in the therapy sessions ( one time each ) .", "label": "", "metadata": {}, "score": "79.50955"}
{"text": "Quitting may take several tries .There are two parts to quitting : quitting and staying quit .Staying quit is the challenge .People quit for two weeks , six months , even five years , and then they get into a situation that sparks the craving and awakens the receptors in their brain , and they get started again .", "label": "", "metadata": {}, "score": "79.641106"}
{"text": "Participants with missing CO validation at 4 weeks were considered smokers at 4 weeks and at 12 weeks .We also calculated 12 weeks of sustained abstinence in accord with the Russell standard 14 as a self - report of smoking no more than 5 cigarettes since the TQD , validated by CO concentrations during weeks 1 through 4 as aforedescribed .", "label": "", "metadata": {}, "score": "79.66874"}
{"text": "JAMA 296:56 - 63 PubMed CrossRef .Lovibond SH , Lovibond PF ( 1995 ) Manual for the Depression Anxiety Stress Scales , 2nd ed .", "label": "", "metadata": {}, "score": "79.68299"}
{"text": "Each question had an associated score , and the total score achieved by the participant determined their level of nicotine dependency .Use of smokeless tobacco was assessed weekly at weeks 9 - 12 and again at week 26 with a self completion questionnaire , modified from one designed for and implemented in previous varenicline studies to collect information about nicotine use .", "label": "", "metadata": {}, "score": "80.042755"}
{"text": "\" Some patients prescribed Chantix to quit smoking have anecdotally reported a reduction in consumption of alcohol as well , and controlled studies in animals and humans have supported the effect .", "label": "", "metadata": {}, "score": "80.10613"}
{"text": "20 - 23 Combination therapy could provide a clinical option for patients concerned about weight gain and for whom weight gain may undermine smoking cessation in the short term .", "label": "", "metadata": {}, "score": "80.123245"}
{"text": "All analyses were performed using the intention - to - treat approach .Smoking abstinence end points at 12 weeks ( end of treatment ) , 26 weeks , and 52 weeks were analyzed separately using logistic regression .", "label": "", "metadata": {}, "score": "80.19505"}
{"text": "The study consisted of a telephone screening call , 11 clinic visits , and 3 follow - up telephone calls ( Figure ) .One follow - up telephone call occurred during the medication phase at the time of the target quit date and 2 calls occurred after the medication phase .", "label": "", "metadata": {}, "score": "80.25665"}
{"text": "Adverse events during treatment ( all causes ) and discontinuation of treatment because of adverse events .Figures are numbers ( percentages ) of participants .", "label": "", "metadata": {}, "score": "80.393684"}
{"text": "Addiction 2008 , 103 : 146 - 154 .PubMed View Article .McEwen A , Hajek P , McRobbie H , West R : Manual Of Smoking Cessation : A Guide For Counsellors And Practitioners .", "label": "", "metadata": {}, "score": "80.4249"}
{"text": "The screening visit also included a physical examination , a 12-lead electrocardiogram ( ECG ) , and a blood draw to determine liver function .", "label": "", "metadata": {}, "score": "80.715996"}
{"text": "( with response options of \" much stronger , \" \" slightly stronger , \" \" same as before , \" \" slightly weaker , \" and \" much weaker \" ) and \" Have you found cigarettes more or less enjoyable than usual in the last week ? \"", "label": "", "metadata": {}, "score": "80.80321"}
{"text": "The authors also thank Pfizer for the generous donation of study drug .Conflicts of interest .The authors have no conflicts of interest to declare .", "label": "", "metadata": {}, "score": "80.809616"}
{"text": "ETG testing was conducted weekly by Phamatech Laboratories ( San Diego , CA , USA ) .Complete blood counts and hepatic function panels were performed by Quest Diagnostics .", "label": "", "metadata": {}, "score": "80.91707"}
{"text": "Study participants primed with these emotions expressed ... read more .Weight gain is a predictable occurrence for smokers who have recently ... read more .", "label": "", "metadata": {}, "score": "80.97471"}
{"text": "Further research is required to determine the role of combination therapy in smoking cessation .Figures in this Article .Smoking accounts for 62 % of deaths among female smokers and 60 % of deaths among male smokers .", "label": "", "metadata": {}, "score": "81.28473"}
{"text": "Thirty - five subjects completed the 12-week medication cycle and 34 subjects completed the study through week 16 .Diary data from one subject was dropped from data analysis because he told study staff that he had shared his username and password with his girlfriend so that she could monitor his alcohol intake and implied that his diaries were , therefore , inaccurate .", "label": "", "metadata": {}, "score": "81.48204"}
{"text": "Neuropsychopharmacology 36:603 - 615 PubMed CrossRef .Fucito LM , Toll BA , Wu R , Romano DM , Tek E , O'Malley SS ( 2011 )", "label": "", "metadata": {}, "score": "81.56061"}
{"text": "Computerized alcohol use diaries .Subjects were given a coded username and password to log on to the study server where they entered the number of alcoholic drinks and cigarettes they consumed during each 24-h period .", "label": "", "metadata": {}, "score": "81.70261"}
{"text": "Main outcome measures The primary end point was the four week continuous abstinence rate at the end of treatment ( weeks 9 - 12 ) confirmed with cotinine concentration .", "label": "", "metadata": {}, "score": "81.74594"}
{"text": "Flow of Participants in Tobacco - Dependence Treatment Study .For each participant , demographic data , tobacco use history , and self - reported information on race and ethnicity according to National Institutes of Health guidelines and recommendations for federally funded research were collected .", "label": "", "metadata": {}, "score": "81.78366"}
{"text": "Participants .They had to be prepared to adhere to the protocol and provide informed consent .Women of childbearing age were included if they were not pregnant or breast feeding and had agreed to practise effective contraception for at least one month before and for the duration of the trial .", "label": "", "metadata": {}, "score": "81.95671"}
{"text": "All tests were 2-tailed .Up to 5 lapses ( single instances of smoking ) since the TQD were allowed with no smoking at all during Week 4 .", "label": "", "metadata": {}, "score": "81.97193"}
{"text": "Copeland AL , Martin PD , Geiselman PJ , Rash CJ , Kendzor DE .Smoking cessation for weight - concerned women .Addict Behav .", "label": "", "metadata": {}, "score": "82.14744"}
{"text": "Copeland AL , Martin PD , Geiselman PJ , Rash CJ , Kendzor DE .Smoking cessation for weight - concerned women .Addict Behav .", "label": "", "metadata": {}, "score": "82.14744"}
{"text": "Clinical practice guideline .Treating tobacco use and dependence : 2008 update .US Department of Health and Human Services : Public Health Service , 2008 .", "label": "", "metadata": {}, "score": "82.18894"}
{"text": "Why study longer pre - quitting use of varenicline when we do n't yet know whether varenicline is more effective long - term than quitting cold turkey ?", "label": "", "metadata": {}, "score": "82.49681"}
{"text": "Appenzeller BM , Agirman R , Neuberg P , Yegles M , Wennig R ( 2007 )Segmental determination of ethyl glucuronide in hair : a pilot study .", "label": "", "metadata": {}, "score": "82.54491"}
{"text": "They are ashamed to admit to their physician that they 've relapsed and need help quitting again .The American Lung Association estimates the average person tries to quit four times - and as many as eight times - before successfully overcoming tobacco addiction .", "label": "", "metadata": {}, "score": "82.57309"}
{"text": "Because of the lack of guidelines for behavioural support or counselling for cessation of smokeless tobacco , participants were offered brief behavioural support or counselling at the discretion of the investigator and in accordance with local standard practice .", "label": "", "metadata": {}, "score": "82.68073"}
{"text": "The non - reactors in the two study arms did not differ in urges to smoke or other withdrawal symptoms at 24 hours , 1 or 4 weeks after TQD .", "label": "", "metadata": {}, "score": "82.735085"}
{"text": "\" The more we can reduce these negative symptoms associated with quitting the better experience of the smoker and this may mean that even if they do n't quit this time , they will be encouraged to try again .", "label": "", "metadata": {}, "score": "82.80211"}
{"text": "\" The more we can reduce these negative symptoms associated with quitting the better experience of the smoker and this may mean that even if they do n't quit this time , they will be encouraged to try again .", "label": "", "metadata": {}, "score": "82.80211"}
{"text": "Dr Ebbert reports serving as an investigator for clinical trials funded by Pfizer , receipt of consultancy fees from GlaxoSmithKline , research support from Pfizer , and research support from Orexigen and JHP Pharmaceuticals outside of the current study .", "label": "", "metadata": {}, "score": "82.92342"}
{"text": "Lindson N , Aveyard P : An updated meta - analysis of nicotine preloading for smoking cessation : investigating mediators of the effect .Psychopharmacology ( Berl ) 2011 , 214 : 579 - 592 .", "label": "", "metadata": {}, "score": "82.99513"}
{"text": "Smoking cessation meds shows promise as alcoholism treatment , study suggests .Date : .A medication commonly used to help people stop smoking may have an unanticipated positive side effect for an entirely different vice : drinking alcohol .", "label": "", "metadata": {}, "score": "83.431366"}
{"text": "1217- 1222 PubMed .Hajek PWest RFoulds JNilsson FBurrows SMeadow A Randomized comparative trial of nicotine polacrilex , a transdermal patch , nasal spray , and an inhaler .", "label": "", "metadata": {}, "score": "83.46571"}
{"text": "1217- 1222 PubMed .Hajek PWest RFoulds JNilsson FBurrows SMeadow A Randomized comparative trial of nicotine polacrilex , a transdermal patch , nasal spray , and an inhaler .", "label": "", "metadata": {}, "score": "83.46571"}
{"text": "Keywords .Smoking cessation Varenicline Nicotine patch .Background .Nicotine replacement treatment ( NRT ) and varenicline are both effective in helping smokers stop smoking [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "83.50005"}
{"text": "Results from the Epidemiologic Catchment Area ( ECA ) Study .JAMA 264:2511 - 2518 PubMed CrossRef .Room R ( 2004 )Smoking and drinking as complementary behaviours .", "label": "", "metadata": {}, "score": "83.560974"}
{"text": "( from \" not at all \" to \" all of the time \" ) and \" How strong have the urges been ? \"( from \" no urges \" to \" extremely strong \" ) .", "label": "", "metadata": {}, "score": "83.60499"}
{"text": "Physicians should claim only the credit commensurate with the extent of their participation in the activity .Physicians who complete the CME course and score at least 80 % correct on the quiz are eligible for AMA PRA Category 1 Credit TM .", "label": "", "metadata": {}, "score": "83.94682"}
{"text": "In the analyses of changes in smoking behavior before quitting , only participants who provided data were included ( ie , no imputations were used ) .", "label": "", "metadata": {}, "score": "84.005585"}
{"text": "PubMed View Article .West R , Hajek P : Evaluation of the mood and physical symptoms scale ( MPSS ) to assess cigarette withdrawal .", "label": "", "metadata": {}, "score": "84.33239"}
{"text": "Of those who try to quit \" cold turkey \" without some sort of help , it 's estimated that only 5 to 8 percent are successful .", "label": "", "metadata": {}, "score": "84.401306"}
{"text": "As in many such study populations , subject retention was problematic ( Howard 1992 ) and our attrition rate was magnified by the long study duration ( 16 weeks ) .", "label": "", "metadata": {}, "score": "84.45033"}
{"text": "Participants lost to follow - up were considered to be smoking .Abstinence at 12 weeks was defined as self - reported sustained abstinence since TQD ( with up to 5 lapeses allowed ) but it was not biochemically validated .", "label": "", "metadata": {}, "score": "84.460144"}
{"text": "Brief Summary .The purpose of this study is to determine whether extended pretreatment with varenicline ( Chantix ) is more efficacious for smoking cessation than standard pretreatment , how well varenicline is tolerated in heavy drinking smokers , and whether varenicline reduces alcohol consumption .", "label": "", "metadata": {}, "score": "84.64155"}
{"text": "Other data were collected over the phone at the end of weeks 1 and 2 , at 24 hours after the TQD , and at week 16 ( 3 months after the TQD ) .", "label": "", "metadata": {}, "score": "84.876686"}
{"text": "The most common explanations given for termination of study participation were time constraints , upcoming travel , and change in job or living arrangement .Five drop outs were due to adverse events ( AEs ; see below ) .", "label": "", "metadata": {}, "score": "85.09235"}
{"text": "Exclusion of this participant did not alter the results .One participant moved away from London before the 4-week post - TQD session but was validated as abstinent using a mailed salivary cotinine kit .", "label": "", "metadata": {}, "score": "85.146515"}
{"text": "Now , ... read more .While treatments for alcohol abuse ... read more .Compared with smokers who are not depressed , those who suffer from a major depressive disorder have greater ... read more .", "label": "", "metadata": {}, "score": "85.502556"}
{"text": "The institutional review boards of Mayo Clinic and the University of Minnesota approved all study procedures .The trial ended when recruitment was achieved and follow - up was completed .", "label": "", "metadata": {}, "score": "85.714905"}
{"text": "Alternatively , the motivation to quit could be lower for smokeless tobacco than for smoking because of the perception that smokeless tobacco is less harmful .", "label": "", "metadata": {}, "score": "86.22496"}
{"text": "A total of 101 volunteers were enrolled and randomized .Figure 1 shows the flow of participants through the trial .Table 1 gives baseline characteristics of the participants .", "label": "", "metadata": {}, "score": "86.26994"}
{"text": "It will be reviewed by JAMA Internal Medicine editors .You will be notified when your comment has been published .Comments should not exceed 500 words of text and 10 references .", "label": "", "metadata": {}, "score": "86.28854"}
{"text": "Remember , quitting tobacco use for good takes more than a pill .Understanding how this chronic disease works and providing personalized , comprehensive treatments and support will help more people be successful in ending their dependence on nicotine .", "label": "", "metadata": {}, "score": "86.48958"}
{"text": "Results .Baseline and demographic characteristics .Participants averaged over 20 years of use of smokeless tobacco , and at baseline used it about 15 - 16 times a day .", "label": "", "metadata": {}, "score": "86.84971"}
{"text": "Subjects were recruited based on heavy drinking behavior , not smoking behavior -- though the recruits did smoke 4 cigarettes a day on average .15 subjects ( 8 men and 7 women ) were brought to the laboratory for six different sessions .", "label": "", "metadata": {}, "score": "87.07779"}
{"text": "Table 3 shows the rates of continuous validated abstinence ( not a puff since the TQD ) at 24 hour and 1 week and the Russell Standard sustained validated abstinence at 4 weeks ( up to 5 cigarettes allowed with no smoking during the previous week ) .", "label": "", "metadata": {}, "score": "87.27552"}
{"text": "Empirical evidence suggests this is not true for smoking cessation studies in which participants who drop out are likely to have relapsed to smoking .26 However , the assumption of this study that all who have dropped out have resumed smoking could underestimate actual abstinence rates .", "label": "", "metadata": {}, "score": "87.3978"}
{"text": "References .Stead LF , Perera R , Bullen C , Mant D , Lancaster T : Nicotine replacement therapy for smoking cessation .Cochrane Database Syst Rev 2008 .", "label": "", "metadata": {}, "score": "87.520935"}
{"text": "J Clin Pharmacol 2006 ; 46 : 1439 -48 .Gonzales D , Rennard SI , Nides M , Oncken C , Azoulay S , Billing CB , et al .", "label": "", "metadata": {}, "score": "87.62819"}
{"text": "Daily heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on an occasion .Exclusion Criteria : .", "label": "", "metadata": {}, "score": "88.05104"}
{"text": "[ Time Frame : First 3 weeks of pretreatment ] [ Designated as safety issue : No ] .Current Secondary Outcome Measures ICMJE ( submitted : January 28 , 2013 ) .", "label": "", "metadata": {}, "score": "88.05381"}
{"text": "The primary end point was the biochemically confirmed prolonged and 7-day point - prevalence smoking abstinence rates at week 12 .End points were selected using recommended outcomes for tobacco intervention studies .", "label": "", "metadata": {}, "score": "88.20476"}
{"text": "All authors had full access to all of the data ( including statistical reports and tables ) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis .", "label": "", "metadata": {}, "score": "88.441635"}
{"text": "Smoking is more prevalent in heavy drinkers ( Mello et al .1987 ; Room 2004 ) and alcohol potentiates nicotine reward ( Rose et al .", "label": "", "metadata": {}, "score": "88.474075"}
{"text": "Methods .Subjects .Subjects were invited to participate in a smoking cessation study .The words \" alcoholic \" and \" alcohol abuse \" were never used in conjunction with recruitment , screening , or data collection , and subjects were not treatment - seeking for alcohol abuse .", "label": "", "metadata": {}, "score": "88.52617"}
{"text": "PubMed View Article .Farley AC , Hajek P , Lycett D , Aveyard P : Interventions for preventing weight gain after smoking cessation .Cochrane database of systematic reviews ( Online ) 2012 , 1 : CD006219 .", "label": "", "metadata": {}, "score": "88.612274"}
{"text": "15 Point prevalence was defined as CO - confirmed self - reported tobacco cessation in the previous 7 days . and \" Since 14 days after your target quit date , have you used any tobacco on at least 1 day in each of 2 consecutive weeks ? \"", "label": "", "metadata": {}, "score": "89.71144"}
{"text": "Sample size .To allow for participant attrition , the study aimed to randomise between 110 and 120 participants .Statistical analysis .Differences between the study arms were assessed by analysis of variance for continuous variables and chi - square for categorical variables .", "label": "", "metadata": {}, "score": "90.02339"}
{"text": "As the motivation among users to quit was high in this study , it seems likely that there is an urgent need to provide more support and encouragement to smokeless tobacco users who would like to quit .", "label": "", "metadata": {}, "score": "90.32454"}
{"text": "9 While there are several hundred studies on smoking cessation that have documented the efficacy of pharmacotherapy and behavioural support , there are far fewer studies on cessation of smokeless tobacco , perhaps because of the widely held belief that it is less harmful than smoking .", "label": "", "metadata": {}, "score": "90.386345"}
{"text": "The Modified Cigarette Evaluation Questionnaire 12 has 12 items asking about a range of reactions to cigarettes ( eg , \" Was smoking satisfying ? \"", "label": "", "metadata": {}, "score": "90.41765"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator )", "label": "", "metadata": {}, "score": "90.60646"}
{"text": "University of Texas M. D. Anderson Cancer Center .( 2013 , March 27 ) .Anti - smoking drug improves smokers ' chances of stopping , study finds .", "label": "", "metadata": {}, "score": "90.889435"}
{"text": "Participants were contacted for the final follow - up 12 weeks after the TQD .Participants received two payments of \u00a3 15 at sessions one and four weeks post - TQD .", "label": "", "metadata": {}, "score": "91.010895"}
{"text": "\" Did you enjoy smoking ? \" )It was administered at each prequit contact .Participants were also asked to estimate the mean number of cigarettes smoked per day over the previous week .", "label": "", "metadata": {}, "score": "91.45918"}
{"text": "Prev Med 2004 ; 38 : 498 -502 .Faessel HM , Gibbs MA , Clark DJ , Rohrbacher K , Stolar M , Burstein AH .", "label": "", "metadata": {}, "score": "91.679306"}
{"text": "Similarly , at weeks 9 - 26 there were 14 non - responders ( seven ( 6 % ) and seven ( 5 % ) , respectively ) who started smoking cigarettes , pipes , or cigars .", "label": "", "metadata": {}, "score": "91.79112"}
{"text": "28 Furthermore , cotinine concentrations and Fagerstr\u00f6m test scores did not predict outcome , which is contrary to findings in the smoking cessation literature .17 18 Because the modified Fagerstr\u00f6m test we used is a novel assessment , however , there are no comparisons available in the literature at this time .", "label": "", "metadata": {}, "score": "91.7988"}
{"text": "The modified Fagerstr\u00f6m test was developed by the originator of the test for smokers ( K Fagerstr\u00f6m ) but has not yet been validated , and further studies evaluating the utility of this test in measuring nicotine dependence among smokeless tobacco users are warranted .", "label": "", "metadata": {}, "score": "92.12603"}
{"text": "Critical revision of the manuscript for important intellectual content : Hajek , McRobbie , Myers , Stapleton , and Dhanji .Financial Disclosure : Drs Hajek and McRobbie have received research funding from and provided consultancy to manufacturers of smoking cessation medications .", "label": "", "metadata": {}, "score": "92.18735"}
{"text": "Biol Psychiatry 69:1075 - 1082 PubMed CrossRef .JAMA 296:47 - 55 PubMed CrossRef .Heatherton TF , Kozlowski LT , Frecker RC , Fagerstr\u00f6m KO ( 1991 )", "label": "", "metadata": {}, "score": "92.4902"}
{"text": "All authors were involved in interpretation of data , drafting the article , reviewing the article for important intellectual content , and the decision to submit the article for publication .", "label": "", "metadata": {}, "score": "92.934845"}
{"text": "PubMed View Article .Gonzales D , Rennard SI , Nides M , Oncken C , Azoulay S , Billing CB , Watsky EJ , Gong J , Williams KE , Reeves KR , et al .", "label": "", "metadata": {}, "score": "92.97007"}
{"text": "Smokers seeking treatment were recruited in April 2011 through local advertisments .Volunteers were included if they were aged 18 and over , were not breastfeeding or pregnant , and had no current psychiatric or other serious illness .", "label": "", "metadata": {}, "score": "93.242935"}
{"text": "Setting Medical clinics ( mostly primary care ) in Norway and Sweden .Participants were excluded if they used any other form of tobacco ( except smokeless tobacco ) or medication to stop smoking within three months of screening or had any pre - existing medical or psychiatric condition .", "label": "", "metadata": {}, "score": "93.35032"}
{"text": "Mello NK , Mendelson JH , Palmieri SL ( 1987 )Cigarette smoking by women : interactions with alcohol use .Psychopharmacology ( Berl )93:8 - 15 CrossRef .", "label": "", "metadata": {}, "score": "93.52516"}
{"text": "2033- 2038 PubMed Link to Article .Figures .Figure 1 .Flow of participants through the trial .TQD indicates target quit date .Changes in cigarette consumption and smoke intake before the target quit date .", "label": "", "metadata": {}, "score": "94.10931"}
{"text": "By using it you agree that that you are requesting the material solely for personal , non - commercial use , and that it is subject to the AMA 's Terms of Use .", "label": "", "metadata": {}, "score": "94.24846"}
{"text": "Funding / Support : The clinical trial was supported by National Institutes of Health ( NIH ) grant CA 138417 ( primary investigator , Dr Ebbert ) .", "label": "", "metadata": {}, "score": "94.44502"}
{"text": "Chantix Double - blind Smoking \u03b14\u03b22 Hazardous drinking Abuse .ClinicalTrials.gov Identifier : NCT01011907 .Introduction .Alcoholism has immense social , medical , and financial costs .", "label": "", "metadata": {}, "score": "94.47543"}
{"text": "University of Texas M. D. Anderson Cancer Center . \"Anti - smoking drug improves smokers ' chances of stopping , study finds . \"ScienceDaily .", "label": "", "metadata": {}, "score": "94.55052"}
{"text": "University of Texas M. D. Anderson Cancer Center . \"Anti - smoking drug improves smokers ' chances of stopping , study finds . \"ScienceDaily .", "label": "", "metadata": {}, "score": "94.55052"}
{"text": "Participants attended at baseline , one week prior to TQD , on TQD , and weekly up to week 4 post - TQD .Informed consent was taken at the baseline session .", "label": "", "metadata": {}, "score": "95.12808"}
{"text": "20 21 The high quit rate in our placebo group could reflect a high motivation to quit among all participants , especially as we offered limited behavioural support .", "label": "", "metadata": {}, "score": "95.221466"}
{"text": "The study sample profile was similar to that of other smokers attending the host stop - smoking service , with a mean age of 46 and a high level of cigarette dependence .", "label": "", "metadata": {}, "score": "95.268555"}
{"text": "Dr Hays reports serving as an investigator for clinical trials funded by Pfizer .Dr Hurt reports receipt of consulting fees from Pfizer , an unrestricted grant from Pfizer Medical Education Group , and provision of expert testimony in Florida tobacco litigation cases .", "label": "", "metadata": {}, "score": "95.47485"}
{"text": "Ethical approval : This study was approved by the institutional review boards and independent ethics committees and all participants gave written informed consent .References .", "label": "", "metadata": {}, "score": "95.964615"}
{"text": "Funding :This work was supported by Pfizer .KF , HG , and ST did not receive any financial support with respect to the writing or development of this manuscript .", "label": "", "metadata": {}, "score": "96.59931"}
{"text": "Jha P , Ramasundarahettige C , Landsman V , et al . 21st- century hazards of smoking and benefits of cessation in the United States .", "label": "", "metadata": {}, "score": "97.17936"}
{"text": "JAMA 2006 ; 296 : 47 -55 .Jorenby DE , Hays JT , Rigotti NA , Azoulay S , Watsky EJ , Williams KE , et al .", "label": "", "metadata": {}, "score": "97.590576"}
{"text": "Addict Behav .NHS , The Information Centre , Statistics on NHS Stop Smoking Services : England , April 2009 - March 2010 , Publication Date August 19 , 2010 , Table 4.4 .", "label": "", "metadata": {}, "score": "98.14424"}
{"text": "Contributors : KF and MMet participated in the design of the study .KF , ST , and HG participated in the collection of data .", "label": "", "metadata": {}, "score": "98.31328"}
{"text": "A randomized , blinded , placebo - controlled clinical trial was conducted at Mayo Clinic in Rochester , Minnesota , a Mayo Clinic Health System site in La Crosse , Wisconsin , and the University of Minnesota in Minneapolis between October 2009 and April 2013 .", "label": "", "metadata": {}, "score": "98.97978"}
{"text": "All authors made substantial contributions to conception and design , or acquisition of data , or analysis and interpretation of data ; drafting the article or revising it critically for important intellectual content ; and final approval of this version of the manuscript .", "label": "", "metadata": {}, "score": "100.403244"}
{"text": "If your institution uses Athens or Shibboleth authentication , please contact your site administrator to receive your user name and password .What is this ?", "label": "", "metadata": {}, "score": "100.52458"}
{"text": "If your institution uses Athens or Shibboleth authentication , please contact your site administrator to receive your user name and password .What is this ?", "label": "", "metadata": {}, "score": "100.52458"}
{"text": "If all authors have none , check \" No potential conflicts or relevant financial interests \" in the box below .Please also indicate any funding received in support of this work .", "label": "", "metadata": {}, "score": "100.838486"}
{"text": "Authors ' Affiliations .UK Centre for Tobacco Control Studies , Wolfson Institute of Preventive Medicine , Barts & The London School of Medicine and Dentistry , Queen Mary , University of London .", "label": "", "metadata": {}, "score": "101.77911"}
{"text": "It 's not about willpower .There is a pervasive notion that quitting is about willpower .Family members often question in frustration why their loved ones ca n't just give up smoking .", "label": "", "metadata": {}, "score": "102.500824"}
{"text": "Author Contributions : Dr Hajek had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis .", "label": "", "metadata": {}, "score": "102.74777"}
{"text": "2033- 2038 PubMed Link to Article .Correspondence .The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians .", "label": "", "metadata": {}, "score": "103.28555"}
{"text": "Arch Fam Med .This feature is provided as a courtesy .By using it you agree that that you are requesting the material solely for personal , non - commercial use , and that it is subject to the AMA 's Terms of Use .", "label": "", "metadata": {}, "score": "103.30754"}
{"text": "Ethical approval was obtained from the NHS National Research Ethics Service ( Approval reference 10/H0709/85 ) .Results .A total of 117 volunteers were enrolled and randomised .", "label": "", "metadata": {}, "score": "103.73147"}
{"text": "Critical revision of the manuscript for important intellectual content : Hatsukami , Croghan , Schroeder , Allen , Hays , Hurt .Statistical analysis : Schroeder .", "label": "", "metadata": {}, "score": "104.69462"}
{"text": "Access to the PDF is only available via article purchase .", "label": "", "metadata": {}, "score": "105.10081"}
{"text": "Arch Fam Med .References .Jha P , Ramasundarahettige C , Landsman V , et al . 21st- century hazards of smoking and benefits of cessation in the United States .", "label": "", "metadata": {}, "score": "105.59984"}
{"text": "Study concept and design : Croghan , Schroeder , Hurt , Ebbert .Analysis and interpretation of data : Hatsukami , Croghan , Schroeder , Hurt , Ebbert .", "label": "", "metadata": {}, "score": "106.08339"}
{"text": "The initiation of taper down ( week 11 ) was taken as the final data point .Pearson 's correlation analysis , regression analysis , and chi square were conducted using Excel and SPSS .", "label": "", "metadata": {}, "score": "106.15045"}
{"text": "Disclaimer : AAAS and EurekAlert ! are not responsible for the accuracy of news releases posted to EurekAlert ! by contributing institutions or for the use of any information through the EurekAlert system .", "label": "", "metadata": {}, "score": "106.43683"}
{"text": "1 Nicotine Dependence Center , Mayo Clinic , Rochester , Minnesota 2 Department of Psychiatry , University of Minnesota , Minneapolis 3 Family Medicine and Community Health , University of Minnesota , Minneapolis .", "label": "", "metadata": {}, "score": "106.852646"}
{"text": "doi:10.1001/jama.2013.283185 .Athens and Shibboleth are access management services that provide single sign - on to protected resources .They replace the multiple user names and passwords necessary to access subscription - based content with a single user name and password that can be entered once per session .", "label": "", "metadata": {}, "score": "107.160515"}
{"text": "Access to the PDF is only available via article purchase .Varenicline decreases alcohol consumption in heavy - drinking smokers .Jennifer M. Mitchell Affiliated with Ernest Gallo Clinic and Research Center , University of California , San Francisco Department of Neurology , University of California , San Francisco Email author . , Candice H. Teague Affiliated with Ernest Gallo Clinic and Research Center , University of California , San Francisco . , Andrew S. Kayser Affiliated with Ernest Gallo Clinic and Research Center , University of California , San Francisco Department of Neurology , University of California , San Francisco . , Selena E. Bartlett Affiliated with Ernest Gallo Clinic and Research Center , University of California , San Francisco . , Howard L. Fields Affiliated with Ernest Gallo Clinic and Research Center , University of California , San Francisco Department of Neurology , University of California , San Francisco .", "label": "", "metadata": {}, "score": "107.729744"}
{"text": "doi:10.1001/archinternmed.2011.138 .Athens and Shibboleth are access management services that provide single sign - on to protected resources .They replace the multiple user names and passwords necessary to access subscription - based content with a single user name and password that can be entered once per session .", "label": "", "metadata": {}, "score": "109.992966"}
{"text": "Mr Stapleton 's involvement was supported by Cancer Research United Kingdom .Role of the Sponsor : The funders had no role in the design or conduct of the study ; collection , management , analysis , or interpretation of the data ; or preparation , review , or approval of the manuscript .", "label": "", "metadata": {}, "score": "111.651985"}
{"text": "Acquisition of data : Hajek , McRobbie , Myers , Stapleton , and Dhanji .Analysis and interpretation of data : Hajek , McRobbie , Myers , Stapleton , and Dhanji .", "label": "", "metadata": {}, "score": "112.549324"}
{"text": "JAMA 2006 ; 296 : 56 -63 .Nakamura M , Oshima A , Fujimoto Y , Maruyama N , Ishibashi T , Reeves KR .", "label": "", "metadata": {}, "score": "113.37561"}
{"text": "Body Mass Index ( calculated as weight in kilograms divided by the square of height in meters ) less than 15 or greater than 38 or weight less than 45 kg .", "label": "", "metadata": {}, "score": "114.73477"}
{"text": "ScienceDaily .ScienceDaily , 15 February 2012 . . .University of Chicago Medical Center .( 2012 , February 15 ) .Smoking cessation meds shows promise as alcoholism treatment , study suggests .", "label": "", "metadata": {}, "score": "115.548454"}
{"text": "PubMed View Article .Health T , Centre SCI : Statistics on NHS Stop Smoking Services : England , April 2010 - March 2011 .London : The Information Centre , Lifestyle Statistics ; 2011 .", "label": "", "metadata": {}, "score": "116.55372"}
{"text": "Corresponding Author : Jon O. Ebbert , MD , MSc , Mayo Clinic , 200 First St SW , Rochester , MN 55905 ( ebbert.jon@mayo.edu ) .", "label": "", "metadata": {}, "score": "117.212494"}
{"text": "Only content that has not been published , posted , or submitted elsewhere should be submitted .By submitting this Comment , you and any coauthors transfer copyright to the journal if your Comment is posted .", "label": "", "metadata": {}, "score": "119.46977"}
{"text": "University of Chicago Medical Center .\" Smoking cessation meds shows promise as alcoholism treatment , study suggests . \"ScienceDaily .Brown adipose tissue ( BAT ) , also known as brown fat , is one of two types of ... read more .", "label": "", "metadata": {}, "score": "119.846954"}
{"text": "Cite this as : BMJ 2010;341:c6549 .Footnotes .We thank Abegale Templar , of UBC Scientific Solutions , for editorial assistance in the form of proof reading , collation of reviewers ' comments , formatting the manuscript for submission , preparation of figures and tables , and formatting of references .", "label": "", "metadata": {}, "score": "120.08931"}
{"text": "Smokeless tobacco is often considered less harmful than smoking , 7 and this could explain why in Sweden it is used by nearly 30 % of male smokers trying to quit . 8", "label": "", "metadata": {}, "score": "120.19675"}
{"text": "JAMA 2006 , 296 : 47 - 55 .PubMed View Article .JAMA 2006 , 296 : 56 - 63 .PubMed View Article .", "label": "", "metadata": {}, "score": "123.888275"}
{"text": "Results from the National Health Interview Survey .Health on equal terms , 2008-living habits .Ministry of Health and Social Affairs in Sweden and Swedish National Institute of Public Health , 2008 .", "label": "", "metadata": {}, "score": "125.30744"}
{"text": "The use of smokeless tobacco products is increasing in many countries .In Scandinavia the use of smokeless tobacco , specifically snus ( a moist tobacco product , consumed by placing it under the upper lip ) , is well established .", "label": "", "metadata": {}, "score": "128.99823"}
{"text": "This article is distributed under the terms of the Creative Commons Attribution License which permits any use , distribution , and reproduction in any medium , provided the original author(s ) and the source are credited .", "label": "", "metadata": {}, "score": "129.82626"}
